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Abstract 
Cervical cancer is the second most common cancer affecting women and in most 
developing countries it remains the leading cause of cancer deaths. In South Africa, 
more than 3 400 women succumb to the disease every year and 1 in 31 women 
develop cervical cancer. The causative agent for cervical cancer is the Human 
papillomavirus (HPV). High-risk (carcinogenic) HPV types have been linked with 
99% of the incidences of cervical cancer. The most common types identified in almost 
70% of cervical cancer cases worldwide are HPV 16 and 18. HPV infection is very 
common in young healthy women and most immunocompetent individuals can clear 
HPV infection. However, in immunosuppresed women, clearance by host immune 
system is impaired. In addition, multiple HPV infections are quite common in women 
with Human immunodeficiency virus (HIV) infections. 
The objectives of this study were to identify HPV types in South African women who 
also had HIV infection, and secondarily, to determine if recombination of HPV 
genomes occurs. Determining the HPV types circulating in this country is important 
to enable identification of most common HPV types, in order to guide the 
development of vaccines against HPV infection. HPV genotyping was performed by 
the commercial Roche Linear Array HPV Genotyping Test. The most common HPV 
types in South African women with HIV co-infection were HPV 61 (24%, 2611 09), 
HPV 66 (18%, 20/109), HPV 58 (17%, 191109), HPV 53 (17%, 181109), HPV 45 
(16%, 17/109), HPV 18 (16%, 17/109) and HPV 70 (16%, 17/109). Rolling circle 
amplification was performed on one specimen prior to pyrosequencing to detect more 
HPV types. Pyrosequencing detected HPV types 16,30,39,40, 56, 74 and 86. It was 
observed that HPV types other than those included in the commercial test were 
present. These were HPV types 30, 74 and 86. Type-specific PCR was used to 
determine the prevalence of these types among all the women in this study. HPV 30 
prevalence was 15% (16/109), the prevalence of HPV 74 was found to be 13% 
(14/109) and HPV 86 prevalence was only 5% (51109). 
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The full length HPV 39 genome was analysed to detect recombination by primer-
walking and there were no recombination events identified. However, point mutations 
were observed in the El, E21E4, E5 and Ll regions ofHPV 39 genome. 
This study also analysed the variants of HPV 16 among HIV infected women. HPV 
16 is the most studied HPV genome worldwide and sequence variations within the 
genome led to identification of variants. Some of the HPV 16 variants have been 
claimed to be more often associated with disease than others; hence identification of 
variants can potentially predict risk of cervical disease and cancer. In this study, 
variants of HPV 16 were determined within the long control region (LCR). The 
variants of HPV 16; European, African type 1 and 2, Asian and Asian-American, 
were identified among 15 South African women. The most common variant was the 
African type 2 (60%, 9/15) and infection with more than one variant was common. 
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1 Introduction 
Papillomaviruses (PVs) belong to the family Papillomaviridae. This taxonomic family is 
divided into genus, species, types, subtypes and variants (de Villiers et ai., 2004). 
Different PV s are named according to the species they infect as they are species-specific. 
F or example, Bovine PV s infect mostly cattle, cottontail rabbit PV s infect rabbits and 
human PVs infect humans (Howley, 1996). The discovery ofPVs dates back to the early 
1900s when their link to skin warts/papillomas in humans was discovered. Their 
association with cancer was not apparent until experimental work on rabbit 
papillomavirus during the 1930s provided the indication that PV s can cause cancer (Shah 
and Howley, 1996). Further experimentation led to the development of testing methods 
for Human papillomavirus (HPV) DNA. This major breakthrough in the early 1980s 
made it possible to establish the role ofHPV in cervical cancer (Kjaer et ai., 1996). Since 
then, HPV s have been recognised as the causative agents for cervical cancer: HPV shave 
been detected in 99.7% of all cervical cancer cases (Walboomers et aI., 1999). Although 
it is a preventable disease, cervical cancer continues to be the second most common 
cancer in women worldwide (Kjaer et ai., 1996; Walboomers et ai., 1999). 
HPV s consist of a diverse group of viruses that infect the cutaneous area and mucosal 
epithelia (Schiffman and Kjaer, 2003). HPV infection can result in papilloma formation, 
precancerous lesions and cervical cancer (section 1.2). Cervical cancer is not the only 
HPV induced cancer. Other types of human cancers such as skin, anal, head and neck 
cancer, vulvar/vaginal cancer in women and penile cancer in men have been reported to 
be HPV linked (Schiffman and Kjaer, 2003; Hoory et ai., 2008). More than 200 HPV 
types exist, of which more than 100 HPV full genomes are known (Lizano et ai., 2009). 
However, only a few have been classified into distinct categories: HPV s are classified 
into high-risk, low-risk and probable high-risk types based on epidemiological and 
phylogenetic grouping (Munoz et ai., 2003). 'Risk' refers to the oncogenic potential of 
the virus types, therefore defining their link to cervical neoplasia and cervical cancer. The 
high-risk HPV types are strongly associated with the development of malignant lesions 
and cervical cancer. Low-risk HPV types are associated with benign lesions as they are 
associated with a low risk for deVelopment of cancerous lesions (Hoory et ai., 2008). The 
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probable high-risk types have been found in few cases of cervical cancer and there is not 
enough evidence to support their carcinogenicity (Schiffman et ai., 2009). Although HPV 
infection can cause cancer, not all high-risk HPV infections result in cervical cancer. 
Among the high-risk types, HPV 16 and 18 are the major causes of cervical cancer. HPV 
16 and 18 account for about 70% of cervical cancer cases globally (Castle et ai., 2008). 
Often, other cofactors are involved in the carcinogenesis of HPV; these are discussed in 
section 1.6. 
The burden of cervical cancer is more profound in Africa than in economically developed 
countries, due largely to the inadequate screening programmes for the detection of 
cervical lesions (Chirenje, 2005, Moodley et aI., 2006). In South Africa, cervical cancer 
is a major public health challenge as it is the second most common cancer in the country. 
According to the National Cancer registry, the lifetime risk of developing cervical cancer 
in 2001 was 1 in 31 women (Mqoqi et ai., 2004). There is an increased burden of cervical 
cancer due to the high prevalence of Human immunodeficiency virus (HIV) among 
women (Moodley et ai., 2006). The sub-Saharan African region has the highest HIV 
infected population in the world, with 67% of global HIV infections found in this region 
alone. The global statistics on HIV infection indicate that 50% of HN infected people are 
women. In the sub-Saharan region alone, almost 60% of the HIV infected population are 
women (UNAIDS, 2008). This further worsens the plight of women who also acquire 
HPV infection. The impact of HIV in HPV -related disease is discussed in section 1.6. 
In this review, the transmission of HPV, global epidemiology, risk factors for cervical 
cancer and the virus replication will be discussed. HPV -linked transformation of the 
cervix will also be discussed and some of the treatment and prevention strategies for HPV 
infection. 
1.1 Transmission and symptoms of HPV infection 
The specific modes of acquisition of HPV are not well understood but it is presumed that 
infection of actively proliferating basal epithelium through micro-lesions is the point of 
entry for the virus (Schiffman and Kjaer, 2003). Transmission of anogenital HPV types is 
mainly through sexual contact with an infected person (Kjaer et ai., 1996). Non-sexual 
transmission of HPV has been shown in perinatal infection, close non-sexual contact and 
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possibly through indirect transmission via fomites (Wheeler, 2002). Fomites are objects 
that can transmit infectious organisms (viruslbacteria) from one person to another. 
Infection by HPV through the non-sexual transmission is minimal. The modes of 
transmission of HPV among children are controversial but it has been reported that 
mother-to-child transmission can lead to respiratory papillomatosis (Hoory et ai., 2008). 
Some HPV types are acquired as commensals since they are part of the human flora and 
can be isolated from the skin of healthy individuals (Antonsson and Hansson, 2002). 
HPV infects only the stratified squamous epithelial cells of the skin or the anogenital and 
oropharyngeal mucosal membranes in humans (zur Hausen, 2000). The virus was shown 
to be highly species-specific and has been implicated in a wide range of clinical 
manifestations among humans. Most HPV infections are, however, asymptomatic. In 
cases where symptoms are apparent, HPV infection causes warts and lesions in various 
areas (hands, feet, oral cavity and genitals), depending on the HPV type and site of 
infection (Hoory et al., 2008). A few examples of HPV types and the lesions they cause 
are listed in Table 1.1. An HPV infection can spontaneously disappear after about 6-12 
months, until a new HPV type infects the individual (Schiffman and Kjaer, 2003). The 
clearance of HPV infection is initiated by the cell mediated immune system of the host 
(Frazer, 2009). Persistent infection with high-risk HPVs, in combination with certain 
cofactors, can lead to development of pre-malignant lesions as shown in Figure 1.1 (de 
Cremoux et ai., 2003). The period from initial infection to invasive cancer may take 
between 10-20 years, during which a series of events occur (Trottier and Franco, 2006; 
Hoory et ai., 2008). Figure 1.1 illustrates the factors and path linked to the carcinogenesis 
of HPV infection. 
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Table 1. 1: HPV infection and symptoms assoc iated with certain HPV types 
HPVtype Risk~ Sit e of infection Symptoms/type of lesions 
1, 60 cutaneous Plantar warts 
Sb Sb cutaneous Epidermodysplasia verruciformis , 
-
6c,11c low mucosa genital warts 
16, 18 high mucosa Head and neck sec 
16, 18, 31, 33, 45 
, 
high mucosa genital warts, CIN, sec 
a HPV types have been classified into high- and low-risk based on association with cervica l cancer, most of 
the HPVs whose association with cancer is unknown/not yet investigated are not classified (refer to section 
1.5.1). b HPV types associated with malignant cpidcrmodysplasia verrucifonnis lesions. ~ In rare occasions, 
have been associated with carcinomas. d Other high-risk HPV types (Table 1.3) also cause similar 
symptoms. Cervical intracpilhelial neoplasia (CIN), Squamous cell carcinoma (Se C). !-Iead and neck 
carcinomas include cancers of the oral cavity, pharynx and larynx (modified fro m IARC, 2007; Mui'loz el 
al., 2006) 
Transmissioa: geaillli ! ki ..... t0-5kin 1\ roo"'" COflldon : Ond 
D D con~e 11K, other honnoDlll inftocnc:a 
Traaiml Pcnbtenl 
HPV infodioa Parily infection with 
oncogenic OIher S'fb: HIV, 
nu HPVlypes Chlamydia r- nu > Smoking f n Nutrition .. => 
N Low grade Q do High grade Host gnetk IOIIkcup: 
- 1esioas(U>IL): ' ¢=:J _ (HSIL), poly ............ i. HLA CINI C IN2J3 aDd ocher geaa 
D , Viral genetics: ,~ 11 000 G.aoIype, molecular 
cascslycar I lnvain umc.1 C8DC.'er V vaNab 
Figure 1.1 : T he progressio n to cervica l ca rcino ma from t he onset of HPV infeclio n a nd t he r isk-
factors for deve lop me nt o f cervical d isease. The cases/year refer to USA stat istics. Most HPV infections 
clear spontaneously and a signifi cant number of low-grade squamous intraepithelial lesions (LS IL) regress 
to nonnal while only a few high-grade squamous intraepithelial lesions (HSIL) spontaneously regress. 
cervical intraepithe lial neoplasia (CrN), human leukocyte antigen O'ILA) (Modified from Trottier and 
Franco, 2006; Hoory el 01 .• 2008). 
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The cervical lesions resulting from HPV infection have varying severity. These are 
cytologically detennined as atypical squamous cells of unknown significance (ASCUS), 
low-grade squamous intraepithelial lesions (LSI L) and high-grade squamous 
intraepithcliaJ lesions (HSIL). The LSIL encompass the early stage of cervical disease, 
classified histologically as cervical intraepithelial neoplasia 1 (CIN!). HSIL indicates the 
advanced stages of disease, histologically classified as cervical intraepiLhelial neoplasia 
2/3 (C IN2/3) (Wright, 2007). The prevalence of different HPV types in these conditions 
is discussed in section 1.5.3. These conditions refer to squamous-cell carcinoma (SeC) 
conditions but glandular carcinoma can also occur. The gland ular carcinomas are 
commonl y referred to as adenocarcinoma (Ae) (Howley and Lowy, 2007). 
1.2 HPV structure 
All HPVs have a similar genome organization with a total of 8 or 9 open reading frames 
(ORFs). depending on type. They have a double-stranded circular DNA genome of 
approximately 7900bp (Figure 1.2) (Bernard, 2002). The ORFs encode both the non· 
structural (early) and structura1 (late) proteins. The gene products are classified into early 
and late proteins based on functional action timing, The early proteins are transcribed 
from the early promoter and the late proteins are transcribed from the late promoter. The 
two structural late proteins of HPV, L I and L2, assemble to fonn the vira1 capsid. The 
HPV capsid is non-enveloped part icle with a T=7 icosahedral symmetry (Howley, 1996). 
The icosahedron is fonned through the interaction of 72 pentamers of the major capsid 
protein LI. The minor capsid protein L2 assoc iates with the L1 pentamers, and 
constitutes only one tenth of the mass of the viral capsid (Howley, 1996). The non-
structural proteins comprise of a group of early proteins (E t, E2 and E4-E8) although not 
all HPVs have E5 (Schiffman el 01., 2005) and E8 genes. The E8 ORF is very short (12 
amino acids) (Kadaja el al., 2009), therefore it is usually omitted in structural diagrams of 
HPVs. The functions of the different proteins are summarised in Table 1.2, The HPV 
genome also contains a long control region (LCR), which contains regulatory elements 
for replication and transcription (Figure 1.2). 
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Non coding rqlon for regulation ohlrus 
gene expression \ 
LCR 
E7 
Transformation 
proteins 
~, 
- ---Early promoter 
L 
Capsid proteins,,,,---
HPV genome 
7900bp 
' 000 
-
Membrane E5 
signalling 
2000 
Vi rus assembly and 
release 
---- Late promoter 
E1 
DNA 
replication 
proteins 
Figure 1.2: HPV DNA ge nome showing the different open readin g frames (O RF). The E refers to early 
proteins and L refers to the late proteins. The short E8 ORF is omitted. The long control region (LCR). is a 
non-coding region whose role is in regulation of viral gene expression. The early promoter (p97 for HPV 
16) is located next to the origin of replication (ori) site and the late promoter (p670 for HPV 16) is localed 
fu rther downstream of the early promoter. (Modi fied from Doorbar. 2006). 
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Table 1.2: Summary of the functions of HPV proteins. 
HPV Functional Primary role 
protein category 
El Replication ATPase and DNA helicase that recognises and binds to viral origin of 
DNA replication, episomal maintenance, up-regulation of genome 
replication 
E2 Replication, Episomal maintenance, repressor for E6 and E7, interacts with and 
transcription recruits El to origin of replication, induces apoptosis 
E4 Replication, Production of L2, disruption of cytokeratin filaments, induces G2 arrest, 
transcription believed to facilitate virus assembly and release 
E5 Replication, Stimulation of host growth factor receptors and protein kinases, induces 
transcription, unscheduled cell proliferation, inhibits apoptosis, inhibits traffic of 
transformation major histocompatibility complexes to the cell surface 
E6 Replication, Induces DNA synthesis, up-regulates telomerase, prevents cell 
transformation differentiation, interacts with 4 classes of cellular proteins: 
transcriptional co-activators, proteins involved in cell motility, tumour 
suppressors and inducers of apoptosis; and replication and repair factors 
E7 Replication, Up-regulates cell cycle, down-regulates Rb, induces unscheduled cell 
transcription, proliferation, interacts with histone acetyl transferases 
transformation 
E8 Replication Down-regulation of episomal HPV DNA, long-term maintenance of 
HPVDNA 
LI Viral assembly Major capsid protein, interacts with L2, interacts with cell receptors, 
encodes neutraIising epitopes 
L2 Viral assembly, Minor capsid protein, interacts with DNA and delivers it to replication 
Virion transport sites, believed to facilitate virion assembly, encodes linear virus 
neutralising epitopes 
(Thomison et aI., 2008 and IARC, 2007, Kadaja et aI., 2009) 
1.3 HPV replication 
The HPV life cycle is closely linked to the differentiation stages of host epithelial cells, 
and most of the life cycle is restricted to the epithelium (Kadaja et ai., 2009). After 
infection of the basal cells of the epithelia (Figure 1.3), viral DNA is transported to the 
nucleus for transcription and replication. 
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• 
Normal epithelium 
Stratum 
I Comeum 
I Granular laver 
Spinous laver 
keratinisation beQins 
in this zone 
Basal laver 
b 
shedding of mature vitUS 
virus infection of basal cells 
via micro -lesions 
HPV DNA 
amp~ficatjon 
Upon infenwo, HP 
IS lunspotted to tilt 
btul tpIlhtlium 
Maintenance of 
HPV DNA 
HPV-infected epithelium 
Figure 1.3: The inrttlion cycle of HPV. a: The different layers of the normal epithelium are indicated. b: 
The HPV infected epithelium shows the level of replication in the different epithelium layers. HPV DNA 
replication is at low levels within the basal cells and is increased in the granular layer. To complete the life 
cycle, virion production, assembly and release of mature virus occur in the stralUrn corneum (Modified 
from Longworth and Laimins, 2004). 
The mechanism of replication in PV genomes is determined by the state of the genome 
within the host cell and the stage of the virus life cycle (Kadaja el al., 2009). Ln the 
undifferentiated epithelial cells, where non-productive I-IPV infection occurs, HPV DNA 
replication occurs bidirectionally via theta structures. This replication mechanism 
inhiates replication at the origin of replication site under the regulation of E1 and E2 
(Flores and Lambert, 1997; Kadaja el 01. , 2009). However, upon differentiation of cells, 
the mechanism may switch to a unidirectional rolling-circle replication mechanism 
(Flores and Lambert, 1997), which is common in organisms with circular DNA genomes 
and plasmids (Rector el al., 2004). The differentiated epithelial cells are characterised by 
productive HPV infections, and the viral genome is in the episomal form (Thomison el 
01., 2008). 
DNA replication of the Bovine papillomavirus I (SPV) has been extensively studied and 
has therefore provided the background for HPV DNA replication studies. After infection 
of the basal cells of the epithelia. the virus experiences three stages of replication 
(Thomison el al., 2008). The first stage is the propagation of viral DNA to about 50-100 
copies/cell and the second stage is the maintenance of latent infection at low copy 
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numbers in undifferentiated cells (Howley, 1996; Liu and Melendy, 2002). During the 
second stage the virus only replicates in synchrony with host cell cycle, while 
maintaining the episomal state. The final stage is the vegetative replication, which only 
occurs in terminally differentiated cells (Liu and Melendy, 2002; Kadaja et al., 2009). 
Amplification of viral DNA during this phase may be supported by E4 (Thomison et al., 
2008). In this stage, control of copy number appears to be lost with a concomitant 
increase in the viral DNA copy number. Expression of the late proteins, Ll and L2, and 
new virus assembly occurs following vegetative replication. Virus particles are sloughed 
off with dead cells from the epidermis, completing the virus life cycle (Kadaja et al., 
2009). 
Viral replication is regulated by the El and E2 proteins. The El protein enrols cellular 
factors to allow viral DNA replication to proceed in the absence of host cell replication 
(Brown et al., 2008; Thomison et al., 2008). HPV El on its own has low DNA binding 
affinity, but it complexes with E2 and is targeted to the replication origin to initiate DNA 
replication (del Mar Pena and Laimins, 2002; Brown et al., 2008). The levels of El and 
E2 increase upon cellular differentiation due to the ctivation of a late promoter, leading 
to an increase in the genome copy number (Thomison et a!., 2008). The increase in E2 
proteins results in a regulatory effect on the transcription of the major transforming 
proteins E6 and E7 (section 1.4). 
1.4 Transformation and progression to cancer 
Transformation of host cells is a property of the high-risk HPV types. This is achieved 
through the oncoproteins E6 and E7. E5 is also considered a transforming protein 
although its role in transformation is limited. It has been demonstrated that E5 is not 
expressed in cells with the integrated HPV genome in cancer tumours, and therefore does 
not contribute to transformation (McLaughlin-Drubin and Miinger, 2009). In those HPVs 
that express E5 protein, it enhances the immortalization potential of E6 and E7 (Miinger 
and Howley, 2002; IARe, 2007). E6 and E7 oncoproteins stimulate cell-cycle 
progression by binding to cell-cycle regulators, p53 and retinoblastoma (Rb), 
respectively, which induces transformation of HPV-infected basal cells. E6 binds to p53 
and stimulates its degradation through an ubiquitin-dependent protease system 
(Longworth and Laimins, 2004). Normal function of p53 protein is to arrest cells in G1 
phase following DNA damage during viral infection, thereby inducing apoptosis in the 
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affected cells. The blocking of apoptosis through degradation of p53 can lead to 
progression to malignancy (Longworth and Laimins, 2004). Expression of high-risk HPV 
E6 and E7 keeps the cells immortalised through their interaction with p53 and Rb 
proteins (McLaughlin-Drubin and MOnger, 2009). 
The E6 and E7 of low-risk HPV s are not capable of inducing transformation despite their 
ability to bind the cell-cycle regulators. This is due to a difference in the amino acid 
composition of the binding sites between the high- and low-risk HPV s (Longworth and 
Laimins, 2004). The binding of low-risk HPV E6 protein to p53 occurs in a manner that 
does not induce the degradation of p53. High-risk HPV E7 binds to Rb with increased 
efficiency than low-risk HPV E7, and targets it for degradation. Low-risk HPV E7 is 
unable to facilitate degradation of Rb due to decreased affinity in binding sites between 
the high- and low-risk HPVs (MOnger and Howley, 2002; Longworth and Laimins, 
2004). 
The integration of HPV genome into host DNA by non-homologous recombination often 
disrupts the EIlE2 ORFs of viral genome leading to the loss of expression ofE2 (Figure 
1.3) (Jeon et al., 1995; Kurvinen et al., 2000). Integration occurs when El, which is 
responsible for episomal genome maintenance, is insufficiently produced (Thomison et 
al., 2008). When the genome is in episomal condition, the E2 protein regulates the 
expression of E6 and E7 proteins by suppressing the E61E7 p97 gene promoter. This 
regulatory effect of E2 is lost upon integration, thus E6 and E7 transcription is up-
regulated. This leads to an irreversible commitment by cells to enter S phase and replicate 
as cell-cycle regulators are disrupted by E6 and E7 (Longworth and Laimins, 2004). 
Progression to HSIL and cervical cancer may result due to increased E6 and E7 
expression, which increases transformation of the cervix at the transformation zone. In 
LSIL, the high-risk HPV genomes exist as episomes while they are often integrated in 
HSIL and invasive cancer cases (Longworth and Laimins, 2004). This indicates that the 
progression of LSIL to HSIL is linked to integration of HPV DNA (IARC, 2007). HPV 
16 DNA was found to be integrated in about 72% of cervical cancer cases. In contrast, 
HPV 18 was integrated in 100% of cases of cervical cancer, which possibly explains its 
association with more aggressive cancers (Tjalma et al., 2005). 
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Figure 1.3: Integration of HPV DNA. HPV 16 DNA is integrated into the host DNA, resu lt ing in an 
incomplete E2 ORF. The transcription of genes in the integrated genome is regulated by the same 
promoters (p97 and p670) as in the episomal condition. Open reading frame (ORF); Long control region 
(LCR) (Modified from Doorbar and Sterling, 2001). 
1.5 Epidemiology of HPV 
1.5. t Classification 
HPV types arc grouped into two categories on the basis of the site of infection: these are 
the mucosal and cutaneous types (de Vi lliers. 1989). Further classification of HPV into 
high- and low-risk types is dependent on the epidemiological data for the specific types in 
cancers (Schiffman . , al. , 2009). The high- and low- risk HPV types are grouped within 
the mucosal HPVs, while there are a lot more 'unclassified' types which are found within 
the cutaneous HPV types. Figure 1.4 shows the phylogenetic differentiation between 
cutaneous and mucosal HPV types. 
Among the known HPV types, about 40 of them infect the genital tract. Eleven of these 
are consistently classified as high-risk (16, 18,31, 33,35,39, 45,51,52,56 and 58) 
(Munoz et al .. 2003; Bernard, 2005). These HPV types are associated with malignant 
lesions and invasive cancer, as shown in Table 1.1. From the study by Munoz and others 
(2003), 15 HPV types emerged as high-risk, based on their detection in prevalence 
studies. These included the I) mentioned above, and HPV types 59, 68, 73, and 82 
(Table 1.3). The number of putative high-risk types varies from about 13 to 19, which 
highlights the lack of clear-cut criteria for classifying HPV into high- and low-risk groups 
(Mufioz el al.. 2003). As an example to highlight this classification problem, HPV 73, 
which is phylogenetically related to HPV 34 (Figure 1.4), is grouped into high-risk 
category but H.PV 34 remains 'unclassified'. Also of significance is that some studies 
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classified HPV 73 as phylogenetically low-risk type, although it is generally grouped 
together with the high-risk types based on epidemiology studies (Munoz et ai., 2003). 
This shows that although some HPV types may be closely related, their prevalence and 
correlation to cervical cancer within the population can be quite different. The impact of 
this is that classification of HPV may always be under review as more types are 
discovered or as definite evidence of some types in cervical cancer becomes available. 
Table 1.3: Classification of HPV by cervical oncogenicity 
Risk Classification HPVtypes 
High-risk 16,18,31,33,35,39,45,51,52,56,58,59,68,73,82 
Probable high-risk 26,53,66 
Low-risk 6, 11,40,42,43,44,54,61, 70, 72, 81, CP6108 (HPV 89) 
Undetermined risk 34,57,83 
Classification ofHPV into high-, low- and probable high-risk types (Adapted from Baseman and Koutsky, 
2005). This classification system will be referred to in this review and the rest of the document. 
A recent review on the classification of some weakly carcinogenic HPV types showed 
that HPV 68 may be re-classified as a probable high-risk HPV (Schiffman et ai., 2009). 
This is in contrast to the high-risk classification shown in Table 1.3. In addition to the 
probable high-risk group, another classification category has been defined. This is the 
possibly high-risk group, which includes HPVs 26, 53, 66, 70, 73 and 82. According to 
the classification reviews, these HPV types are considered to be possible high-risk types 
since evidence for carcinogenicity is not sufficient (Schiffman et ai., 2009). In 
comparison to the classification in Table 1.3, it shows that HPV 82 and 73 are no longer 
considered as definite high-risk types. Other HPV types which were not studied in the 
IARC meta-analysis (HPV 30, 34, 67, 85 and 97) are phylogenetically related to some 
high-risk types (Figure 1.4, clade a). These are classified as possible high-risk types. This 
classification was based on the lack of sufficient evidence for carcinogenicity (Schiffman 
et ai., 2009). This re-classification of some HPV types clearly highlights the challenges 
faced when attempting to classify HPV types according to carcinogenicity. 
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Figure 1.4: Evolutionary relationship of 65 HPV types classified into mucosal and cutaneous types. 
The full length HPV genome sequences were obtained from the GenBank database (NCBI, 
www.ncbi.nlm.nih.gov) and analysis was performed using MEGA4 program. The evolutionary history was 
inferred using the Neighbor-Joining method (Saitou and Nei, 1987) and the evolutionary distances were 
computed using the Maximum Composite Likelihood method (Tamura et aI., 2004). Mucosal types are 
sub-divided into high- and low-risk, with clades a and b showing species with high- and low-risk HPV 
types, respectively. Some HPV types included in clade a (HPV 30, 69, 70 and 85) are not classified into the 
high-risk category although they are phylogenetically related to the high-risk or probable high-risk types. 
Phylogenetic analysis was conducted in MEGA4 (Tamura et aI., 2007). 
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1.5.2 Global HPV prevalence 
The prevalence of HPV gives a measure of the percentage in a population of people who 
have new, persistent or recurring HPV infection. HPV can be detected in cytologically 
normal women (Clifford et a!., 2005) as well as in most cases of genital neoplasia and 
cancer (Clifford et al., 2006a; Munoz et al., 2003). The distribution of HPV types is 
different according to region and also differs among women with normal Pap smears and 
those with cervical neoplasia and cancer (Clifford et al., 2006a). 
The most common types of HPV in women without cervical abnormalities worldwide, in 
decreasing order of frequency, are HPV 16, 42, 58, 31, 18, 56, 81, 35, 33, 45, and 52 
(Clifford et al., 2005). Sub-Saharan (Nigeria) women, however, are less likely to be 
infected with HPV 16 as compared to their counterparts in Europe, although they could 
be infected with other high- and low-risk HPV types (Clifford et al., 2005). The likely 
reason for this difference seems to be a mutualistic effect between the biological 
properties of the virus and the host immune system (Clifford et al., 2006a). HPV 35 is the 
most common high-risk type among sub-Saharan African (Nigeria) women without 
cervical abnormalities (Clifford et al., 2005). In contrast to this, HPV 83 was found to be 
the most prevalent type in South African women without cervical abnormalities, followed 
by HPV 53 and lastly HPV 16 (Allan et al., 2008). Clearly, this shows that the prevalence 
rates for the different HPV types are different when compared across countries. The 
burden of genital infection and cancers was found to be highest on the African continent 
compared to other regions. The genital tract infection among women with normal 
cytology in Africa is 21.3%, in America 14.5%, in Asia 10.9% and Europe has the least 
infections at 9.7% of the women surveyed (WHOIICO Report, 2009). 
The general distribution of HPV in women worldwide shows that HPV 16 is the most 
common type detected in both normal Pap smears and cervical cancers (Clifford et a!., 
2005; Munoz et a!., 2003). Among women with cervical cancer, Europe and North 
America have a higher than average prevalence of HPV 16 (Clifford et al., 2006a). 
Munoz and others (2003), in a 12 year study of cervical cancers in 9 countries on 
prevalence of HPV, also reported a worldwide prevalence of 58.9% for HPV 16 (Munoz 
et a!., 2003). Their study tested 1918 women with cervical cancer and 1739 of them were 
positive for HPV DNA. From that study they also noted that HPV 18 was the second 
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most common type with an overall prevalence (among 1739 HPV infected women) of 
15%; 3.7%,4.4% and 27.9% in Spain, Colombia and Philippines, respectively (Munoz et 
al., 2003). The highest prevalence of HPV 45 was in the Philippines (15.7%) but it was 
very low in Spain and Colombia. HPV 52 was highest in Peru (8.6%) (Munoz et al., 
2003) and HPV types 31 and 35 were found more commonly in Latin America (Munoz et 
aI., 2003; Clifford et ai., 2006a). The eight most common HPV types detected in cervical 
cancer patients worldwide, in decreasing order of frequency, are HPV 16, 18, 45, 31, 33, 
52,58 and 35 (Munoz et al., 2003). HPV 16 alone accounts for about 56% of all cervical 
cancers (Barnabas et ai., 2006), but it was reported to be more prevalent in squamous cell 
carcinoma (SCC) cases than in adenocarcinoma (AC) cases (Clifford et al., 2006a). The 
prevalence of different HPV types may vary between SCC and AC. For example, the 
occurrence of HPV 16 in women with SCC was shown to be much higher than that of 
HPV 18. In women with AC, however, HPV 18 was more prevalent than HPV 16 
(Clifford et al., 2006a). 
Despite the differences in burden of HPV infection, it is clear that in all the regions there 
are HPV types that are shared between women without cervical abnormalities and those 
with cancer. These are mainly the high-risk types. They are, in no particular order, HPV 
types 16, 18,45,31,33,52,58 and 35. 
1.5.3 HPV types in HSIL, LSIL and ASCUS 
HPV distribution differs significantly between lesions of different severity. There are 
HPV types that are most often found in a particular type of lesion. The HPV types found 
in women with HSIL are similar to those found in cervical cancer, with HPV 16 being the 
most common type. The eight most common HPV types in HSIL, in decreasing order of 
frequency, are 16,31,58,33, 18,33,52, and 35. Surprisingly, HPV 18 seemed to be less 
prevalent in the HSIL across all regions, as it was the third or fourth most common. It is 
also striking that the related HPV 45 is absent in most regions except in South and 
Central America. North, South and Central America recorded HPV 18 as the third most 
common HPV detected in HSIL. In Africa, HPV 18 is the fourth most common (Clifford 
et al., 2006a). This pattern was confirmed from a South African study involving 53 
women with HSIL. In these women, HPV types 16 and 35 emerged as the predominant 
types, with HPV 18 further down the hierarchy of common HPV types in HSIL (Allan et 
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ai., 2008). In addition, HPV 58 and 66 have also been identified among women with 
HSIL in South Africa (Said et ai., 2009). When comparing the HPV distribution in HSIL 
in South Africa to the global distribution, HPV 66 was only observed among South 
African women. HPV types 31, 33 and 45 were not among the common types in the 
South African general population. This reflects the differences that can be found in HPV 
distribution in different regions. 
Of the 8308 HPV cases in a worldwide study by Clifford and colleagues (2006a), 64% 
were positive for LSIL. However, only 3% of the LSIL positive cases came from Africa, 
whereas most of the cases of HPV were from Europe and America (Clifford et al., 
2006a). Due to the small population size of African LSIL cases in that study, the HPV 
distribution in Africa may not be representative of some African countries. From that 
study, HPV 16 emerged as the most common type in all cases of LSIL, followed by HPV 
31, then 51, 53, 56, 52, 18,66, and 58 in decreasing order of frequency. Other HPV types 
were detected as well but only in about 5% of the LSIL cases, showing the wide 
heterogeneity of HPV in LSIL (Clifford et al., 2006a). A different pattern of HPV 
distribution was observed in a study using samples obtained from South Africa only. In 
that study, Allan and others (2008) described HPV 52 as the prominent type, followed by 
types 53, 16 and 35 among 57 women with LSIL (Allan et ai., 2008). HPV 31 and 51 
were not detected from these South African women while HPV 52, less frequent in 
Europe and America, was the most common type in women with LSIL. In these women, 
HPV 16 was the third most common unlike in European and American samples where it 
was the most frequent type. The distribution of HPV in HIV infected women, who were 
at higher risk of infection with more HPV types than HIV negative women, is discussed 
in section 1.6.3.1. 
Few studies report on the HPV types observed in atypical squamous cells of unknown 
significance (ASCUS). One such study was conducted on South African samples, where 
women with ASCUS were most commonly infected with HPV 52, 45, 84, and 16, in 
order of decreasing frequency (Allan et ai., 2008). 
The HPV distribution in the different types of lesions and cervical cancer highlights the 
HPV types that should be of concern in public health sector. In both LSIL and HSIL, only 
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the high-risk HPV types are more prevalent and this increases risk of lesions developing 
to cervical cancer. 
1. 6 Risk factors for HPV infection 
The development to cervical cancer depends on other factors acting together with the 
oncogenic HPV types (de Cremoux et al., 2003). In addition to HPV and other sexually 
transmitted infections (STIs including HIV, Herpes simplex virus type 2 (HSV-2), 
Chlamydia trachomatis), smoking, use of oral contraceptives, immune suppression, 
exposure to UV light, high parity, family history and multiple sexual partners have been 
implicated as co factors for cervical cancer (Marais et ai., 2008; Hoory et ai., 2008; 
Castellsague and Munoz, 2003). These exogenous as well as endogenous factors 
influence progression to HSIL and cervical cancer by increasing damage to tissues 
(Castellsague and Mufioz, 2003; Marais et ai., 2008). Cofactors in cervical cancer can be 
divided into three main groups. These groups consist of environmental/exogenous 
cofactors, viral cofactors and host cofactors. The environmental factors include oral 
contraceptive use, tobacco smoking, diet, cervical trauma, co-infection with HIV and 
other STIs (Castellsague and Munoz, 2003). Viral factors include co-infection with 
specific HPV types or variants, the viral l ad and viral integration into host DNA. The 
host cofactors like hormones, genetic factors and other host immune response factors also 
contribute to progression of cervical disease (Castellsague and Mufioz, 2003). These 
cofactors influence the acquisition of HPV infection; increase the risk of HPV persistence 
and increase the risk of progression from HPV infection to HSIL and invasive cancer 
(Castellsague and Mufioz, 2003). A few of these cofactors are discussed in the following 
sections. 
1.6.1 Environmental factors 
1.6.1.1 Oral contraceptives 
The use of oral contraceptives has been associated mainly with AC in situ. With longer 
periods of oral contraceptive use, the risk of progression to cervical cancer is increased in 
the presence of HPV (Castellsague and Mufioz, 2003). There is no increased risk of 
cervical neoplasia for up to four years of oral contraceptive usage but for longer than five 
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years, there is a four-fold increased risk for invasive cervical cancer and three-fold risk 
for carcinoma in situ (CIS) (Castellsague and Munoz, 2003). 
Hormone related pathways may promote integration of HPV DNA into the host genome, 
although the mechanisms are not clearly understood. The integration of HPV DNA 
results in deregulation of oncogenic proteins E6 and E7 (Section 1.4) (Castellsague and 
Munoz, 2003). Estradiol, an estrogen, was shown to possibly stimulate transcription of 
HPV 16 E6 and E7 within cell lines with integrated HPV 16 (Wheeler, 2002; 
Castellsague and Munoz, 2003). It has been hypothesised that progesterone, which 
suppresses maturation of the cervical epithelium and retards keratinisation, may make the 
cervix more prone to tumour development (Shapiro et ai., 2003). Oral contraceptives 
might also facilitate HPV reactivation or persistence (Castellsague and Munoz, 2003). In 
contrast to the claim that use of oral contraceptives may increase risk of HPV -induced 
cervical neoplasia and cancer, Shapiro and co-workers (2003) argued that there is no 
significant increase in risk (Shapiro et aI., 2003). In South Africa, screening of women 
for HPV infection is relatively uncommon but the use of oral contraceptives as well as 
injectible progesterone is high (Shapiro et al., 2003). This potentially increases the 
number of women who develop cervical disease and cervical cancer. However, in a study 
in South Africa by Shapiro and co-workers (2003) on oral contraceptive use, there was no 
significant increase in the risk of cervical cancer with use of oral contraceptives although 
modest risk of cervical cancer could not be ruled out for oral contraceptive use for over 
10 years or more (Shapiro et ai., 2003). 
1.6.1.2 Parity 
High parity has been found to be consistent with increased risk of both cervical cancer 
and CIS as most of the major studies among HPV positive women reported an increased 
risk of HSILlcervical cancer with increasing number of pregnancies (Wheeler, 2002). 
High parity may increase the risk of cervical cancer because it maintains the 
transformation zone on the exocervix for many years, thereby increasing exposure to 
HPV and other cofactors. Giving birth at an early age, especially when one is already 
infected with HPV, has also been associated with increased risk of cervical cancer 
(Wheeler, 2002). Hormonal changes and immunodepression during pregnancy (high 
estrogen and progesterone levels) may modulate the immune response to HPV and / risk 
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of persistence (Castellsague and Munoz, 2003). The same effect could also result from 
use of hormonal contraceptives, which also increase levels of progesterone and estrogen 
(Castellsague and Munoz, 2003). Hormonal and immunological mechanisms have been 
hypothesized as plausible explanations for the association between parity and 
HSILIcervical cancer among HPV infected women (Castellsague and Munoz, 2003). 
1.6.1.3 Smoking 
Multiple studies conducted on the association of cervical cancer with smoking have 
consistently shown that tobacco smoking increases the risk of developing HSIL and 
cervical cancer (Wheeler, 2002). Malignant transformation of HPV 16-immortalised 
human endo-cervical cells due to cigarette smoke has been proven. Furthermore, nicotine 
and tobacco-specific carcinogens have been detected in cervical mucus of smokers 
(Castellsague and Munoz, 2003; Wheeler, 2002). The inability of tobacco smokers to 
exert an effective immune response against viral infections may also increase the risk of 
developing cervical cancer (Castellsague and Munoz, 2003). 
1.6.2 Host factors 
Some host factors that have been suggested to increase the risk of developing cancer 
include immunosupression and the presence of genetic disorders like Fanconi anaemia. 
Individuals with this disease have a defective DNA repair system, thereby increasing the 
risk of cancer by more than 150 fold, 700 fold and 4000 fold for head, neck and vulvar 
cancer, respectively (Hoory et a/., 2008). Immunosuppression can be caused by several 
conditions including organ transplants and HIV infection. Only the latter is addressed in 
this review. 
1.6.3 Viral factors 
Although HPV plays a significant role in the development of cervical cancer, it has been 
shown that not all HPV types are responsible for cervical disease. This means that the 
development of cervical disease depends on the infecting HPV types. Some HPV types 
have different variants with different oncogenic potential, as has been predicted for some 
HPV 16 variants (Tu et aI., 2006). Co-infection with multiple HPV types, especially 
high-risk, is also associated with a high-risk for CIN. A high HPV viral load predicts an 
increased risk for HSIL or carcinoma, especially in HIV positive women whose viral load 
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is consistently high (Frisch et al., 2000). Co-infection with other viruses like HIV and 
HSV may also aggravate outcome of HPV infection (Palefsky et al., 1991). Only HPV 
infection in women with HIV is discussed below. As discussed in section 1.4, HPV 
integration plays a pivotal role in the transition from CIN to invasive carcinoma since the 
majority of cervical cancer cases have an integrated genome (Tjalma et aI., 2005). 
Therefore, the ability of an HPV type to integrate into the host DNA increases the risk of 
progression to cervical neoplasia and invasive cancer. 
1.6.3.1 HIV and HPV 
HPV infects the epithelial cells while HIV targets the lymphoid tissue cells (zur Hausen, 
2000; Peterlin and Trono, 2003). The difference in the target cells for infection suggests 
that dual infection of same cell is unlikely. The mechanisms of HPV-HIV interaction are 
still poorly understood, although it is known that HIV tat protein stimulates replication of 
HPV through its effect on the LCR (Palefsky, 2006; Vernon et aI., 1993). In some studies 
on the relationship between HPV and HIV infection, it has been shown that interaction 
between HIV and HPV 16 leads to HPV persistence and cervical neoplasia (Palefsky and 
Holly, 2003). This is a result of gradual damage to the immune system and loss of 
immune control in HIV infected individuals, thus leading to the loss of the HPV specific 
immune response (Palefsky, 2006). 
The gradual increase in cases of HPV induced cancer in developed countries may be a 
direct result of the HIV epidemic. HIV positive women show an increased risk of 
infection with HPV (Palefsky and Holly, 2003) compared to HIV negative women. They 
also experience faster progression of cervical abnormalities when compared to HIV 
negative women (Hawes et aI., 2003; Marais et aI., 2008). A high prevalence of CIN was 
detected in HIV positive adults, as well as a notably faster progression to high-grade 
lesions (palefsky and Holly, 2003). There is also a relatively higher prevalence of 
cutaneous and anogenital warts, which also tend to be larger, more numerous and more 
recurrent in HIV infected individuals compared to HIV negative women (Harwood and 
Proby,2001). 
Due to immunosuppression in HIV positive women, there is an increased risk of infection 
by low-risk HPV s that could lead to more cervical disease than in immunocompetent 
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adults (Luque et aI., 1999, Clifford et al., 2006b). The low immunity levels in HIV 
positive individuals seem to allow for HPV DNA viral replication, resulting in increased 
detection of HPV DNA (Palefsky and Holly, 2003). This is because the HIV tat protein 
seems to stimulate the HPV LCR, increasing binding of replication factors (Vernon et al., 
1993). This highlights the inverse relationship between HPV viral load and immune 
competence (Frisch et al., 2000). Individuals with HIV are at an increased risk of having 
HPV induced HSIL when compared to HIV negative women, especially in individuals 
with high-risk HPV types. Low-risk HPV 11 and 61 were found in HIV infected women 
with HSIL and in whom there were no high-risk types detected (Hawes et al., 2003; 
Clifford et aI., 2006b). This suggests that in HIV immunosuppressed women, the low-risk 
HPV types may lead to more severe lesions. 
MUltiple infections with HPV are consistent with loss of immune control (lower CD4+) 
in the HIV positive women hence the increased disease severity (Frisch et aI., 2000). 
HIV -induced immunosuppression impairs the cell-mediated immunity against HPV 
clearance. Therefore, the level of clearance of HPV in these individuals is very low, 
leading to the persistence ofHPV infection (Frisch et al., 2000). 
The most commonly occumng cancers m HIV positive people were found to be 
vulvar/vaginal cancer and cervical cancer in women, penile cancer in men and invasive 
anal cancer in both men and women (Frisch et al., 2000). In separate studies on women 
with HPV in Kenya, Zambia, Zimbabwe, Uganda and South Africa, the results indicated 
an increased risk of cervical disease for HIV positive women (Hawes et aI., 2003; 
Sahasrabuddhe et aI., 2007; Chirenje, 2005; Moodley et al., 2006). Overall, this indicated 
the increased burden of cervical disease on the African continent. The prevalence of HPV 
in Africa increased to 56% in HIV positive women compared with 23% in HIV -negative 
women (Hoory et ai., 2008; Clifford et aI., 2006b). These prevalence rates were observed 
in women with normal cytology. This implies that among women with cervical 
abnormalities and cancer, HPV prevalence rates are more likely to be higher in HIV 
infected women. 
In America, studies investigating the predominant HPV types in HIV positive individuals 
reported higher prevalence of HPV 68, 56, 53 and 16 compared to their HIV negative 
counterparts. HPV 11 and 61 were also found more commonly in HIV positive women 
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with HSIL than in HIV negative women (Luque et al., 2006, Clifford et al., 2006b). In 
studies done in Africa on women co-infected with HIV, the prevalent types in Ugandan 
women were HPV 52, 58 and 16 (Blossom et aI., 2007; Banura et al., 2008). In Zambia, 
the most common HPV types, in decreasing order of frequency, were HPV 52, 61, 58, 53 
81 and 16 (Sahasrabuddhe et aI., 2007). These studies, although in different continents 
(America and Africa), showed that HPV 16 was the third or fourth most common HPV 
type in HIV infected women. Clearly, this shows that in HIV infected individuals, there is 
a shift towards other HPV types in addition to HPV 16, which is otherwise the most 
common type globally. A major difference in HPV 16 distribution was noted in HSIL 
cases where the prevalence of HPV 16 in women with HIV was lower than that in HIV 
negative women (Clifford et aI., 2006b). In a South African study including 37 HIV 
positive women, HPV 45 and 66 were reported to be more common in HIV infected 
women. HPV 18 prevalence was lower in the HIV infected women compared to its 
prevalence in HIV negative women (Marais et al., 2008). In comparison to HPV types in 
other continents, America for example, the distribution of HPV is different to that in 
African countries when considering prevalence rates. These differences in the distribution 
and prevalence patterns of HPV types in different countries necessitate the profiling of 
HPV types in a country. Establishing the diversity of HPV genotypes among HIV-
infected individuals is important if the development of effective vaccines is to be 
successful in South Africa and the Sub-Saharan region. 
1.7 Prevention of infection and treatment of HPV-associated disease 
Currently there is no cure for HPV infection although lesions like warts can be cured. 
Most treatment forms available only target the warts and lesions (LSIL and HSIL) while 
a few may increase killing of the etiological agent (Stanley, 2003). Treatment options for 
most HPV -induced cutaneous warts include the use of cryosurgery with liquid nitrogen, 
hyfrecation and topically administered drugs (Stanley, 2003; Leman and Benton, 2000). 
Recurrence of warts may occur as the virus still persists. Genital lesions can be treated by 
use of topical applications of creams such as imiquimod and 5-Fluorouracil. Imiquimod 
induces a strong T-cell mediated immune response to kill the virus although it (HPV) 
may not completely be eradicated (Stanley, 2003). Although 100% efficacy cannot be 
guaranteed, genital warts and anogenital lesions can be treated by ablative methods, 
including surgical excision. Interferons are also used for the treatment of warts due to 
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their immunostimulatory effects but as with other methods, recurrence rates are high 
(Stanley, 2003). The screening of women for cervical disease (section 2.1) is useful to 
detect LSIL and HSIL (Naucler et ai., 2007) and treatment of these lesions is possible 
through cervical conisation to prevent progression to cervical cancer (Stanley, 2003). 
Despite the availability of several treatment options, recurrence of lesions may occur in 
future. Although LSIL cases can be treated by ablative methods, sometimes it is not 
treated but regular follow-up is recommended to monitor for progression to HSIL since 
the rate of regression of LSIL is high (Stanley, 2003). 
The use of prophylactic vaccines against HPV is most likely to significantly reduce 
incidences of cervical cancer since it has been documented that 100% of cervical cancer 
cases have HPV. Prophylactic vaccination against HPVs 6, 11, 16 and 18 has drastically 
reduced persistent HPV infection and cervical disease incidences (Castle et ai., 2008). 
The two vaccines available (Gardasil produced by Merck pharmaceuticals and Cervarix 
manufactured by GlaxoSmithKline) protect against the types most associated with 
cervical cancer (HPV s 16 and 18). Gardasil also protects against types that cause genital 
warts (HPVs 6 and 11) (Herrero, 2009). The vaccines consist of virus-like particles 
(VLPs) made from Ll proteins, which self-assemble and present epitopes in a similar 
way to the virus without being infectious. Current production of the vaccines is in insect 
cells (Cervarix) and yeast cells (Gardasil). Based on phylogenetic similarities between 
some HPV types, the current vaccines may also protect against types 31 and 45, which 
are closely related to HPV 16 and 18, respectively (Herrero, 2009). Prophylactic 
vaccination before sexual activity therefore is an effective preventive measure against 
HPV infection. HPV infection can also be prevented by abstinence and faithfulness to 
uninfected partner, assuming the candidate is not already infected. Condom usage is also 
advised, although this only provides partial protection against HPV infection (Baseman 
and Koutsky, 2005). 
The differential distribution of HPV types in cervical disease in a region or country has 
important implications for the application and possible future development of vaccines. 
Current prophylactic vaccines do not include some of the HPV types commonly observed 
in South African women with LSIL and HSIL who are infected with HIV. Prevention of 
cervical disease from a broader spectrum of HPV s infecting women would require 
vaccines that include more HPV types (polyvalent vaccines). The successful development 
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of these vaccines can be achieved when the most prevalent types in cervical cancer in a 
region or country are identified. 
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1.8 Objectives of this study 
The distribution of carcinogenic HPV types is region-specific. The high and increasing 
HIV prevalence in South Africa may significantly change the spectrum of HPV s 
associated with cervical disease. The purpose of this study was therefore firstly, to 
investigate the diversity of HPV types in South African women who are HIV positive. 
Most studies investigating HPV types among women have been performed in other 
African countries and few of these were among HIV positive individuals. In this study, 
HPV genotyping was achieved by using the commercial Roche Linear Array HPV 
Genotyping test. Pyrosequencing was also used for HPV genotyping to confirm the 
results of the Roche Linear Array Genotyping test and identify HPV types that are not 
detected by the commercial genotyping test. The prevalence of the HPV types not 
detected by the commercial test was determined by using type-specific peR. 
HIV infected women are often infected with multiple HPV types and have higher viral 
load, providing an ecological niche for recombination between HPV types. The second 
objective was therefore to investigate the possibility of recombination among HPV 
genomes in this popUlation of HIV -infected women. This was achieved by analysis of 
full-length HPV genome through primer walking sequencing. 
The third and final objective was to determine the variants of HPV 16 that exist in 
women with HIV co-infection. This was achieved by amplification of the long control 
region and identification of single nucleotide changes within this region. Some of the 
variants of HPV 16 have been linked to increased rate of progression to disease and these 
have been isolated in other countries. In South Africa, the comparison between variants 
and disease severity has not been studied; therefore, we wanted to investigate the 
correlation between isolated variants and cervical disease severity in patients. 
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2 Introduction 
The long premalignant phase in HPV infections provides the opportunity to detect and 
treat early disease, thereby preventing the progression to cervical cancer (Barnabas et al., 
2006). The high- and low-risk HPV types that can cause disease have been identified and 
their detection in individuals is important for monitoring infected women for disease 
progression. Different assay methods have been developed to detect HPV types in 
epidemiological and clinical studies, with some methods distinguishing up to 37 types 
(Gravitt et al., 1998, 2000; Clavel et al., 1998; Kleter et al., 1998, 1999). It is beneficial 
to identify the most common oncogenic types within populations in order to guide 
vaccine development research. HPV infection is mostly asymptomatic, but also manifests 
more frequently as malignant disease in infections with high-risk HPVs (de Villiers et al., 
2004). This also occurs more often in HIV positive women, hence the need to monitor 
these women for cervical lesions. Primary screening for c rvical disease (section 2.1) has 
been and continues to be practiced in order to identify women at risk of developing 
cervical cancer. Although primary screening has been useful in detecting asymptomatic 
HPV infections, the sensitivity of diagnosis of CIN2/3 is increased by the use of HPV 
DNA testing (Cox, 2006). 
2.1 Screening for cervical disease 
Cervical cancer is a preventable disease in an environment where detection, treatment 
and follow-up facilities for HPV infection are adequate. The Papanicolaou staining test 
(Pap smear) is used as the primary screening method for cervical disease. This procedure 
detects precancerous lesions when used repeatedly (Naucler et al., 2007), but lacks high 
sensitivity. It is also subjective to adequate sampling and owing to the repetitive nature of 
reading, results in greater interpretation errors. Further tests can be performed in women 
with abnormal cytology: this is achieved through colposcopy, biopsy and HPV DNA 
testing. Colposcopy is a technique that uses a colposcope to magnify the cervix in order 
to detect any abnormalities, whereas biopsy involves the removal of a small piece of 
tissue for diagnostic purposes (lARC, 2007). Although they have been widely used in the 
past, serological tests are unreliable in the detection of HPV infection, hence the 
development of more reliable testing methods that target viral DNA (Schiffman and 
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Kjaer, 2003). These technological advances include the Digene HPV Test Hybrid 
Capture 2 (HC2) and polymerase chain reaction (PCR) based methods (section 2.2.2). 
2.2 HPV DNA testing 
Anogenital HPV prevalence m young healthy women is high (Cox, 2006). Most 
infections are transient; however, women with abnormal Pap test results require follow-
up, referral for further testing and treatment when diagnosed with CIN2/3 (Cox, 2006). In 
order to provide cost-effective follow-ups and treatment of CINl, HPV DNA testing can 
be used to determine persistent HPV infections. HPV DNA testing increases the 
identification of women likely to progress to CIN2/3 who require close monitoring. A 
combination of Pap cytology and HPV DNA testing provides 96-100% sensitivity for the 
detection of CIN2/3 and cervical cancer (Cox, 2006). Therefore, detection of HPV DNA 
could be used alongside cytology methods to improve specificity for cervical disease 
(Soderlund-Strand et ai., 2005). This is recommended especially for women 30 years old 
and above. For the clarification of ASCUS, HPV DNA testing can be used together with 
cytology for women of any age (Cox, 2006). The HC2 assay for high-risk HPVs was 
approved by the FDA for cervical cancer screening, and has therefore been incorporated 
into screening programmes in the USA (Wright et ai., 2007). 
2.2.1 Digene Hybrid Capture test for HPV 
The HC2 assay is used in many clinical diagnostic laboratories as the non-PCR HPV 
DNA detection method. The second-generation version of the assay, HC2, has an 
increased sensitivity compared to the first-generation assay, HCl assay (Poljak et ai., 
1999). HC2 is a commercial enzyme-linked immunosorbent assay on cervical scrapings. 
The HC2 assay uses a cocktail of probes for 13 high-risk HPV types (HPV 16, 18, 31, 33, 
35,39,45,51,52,56,58,59 and 68) and five low-risk types (HPV 6, 11,42,43 and 44) 
(Clavel et ai., 1998). The assay is based on sandwich hybridisation using HPV RNA 
probes against HPV DNA. The RNA-DNA hybrids are captured onto the surface of 
microplates coated with monoclonal antibodies specific for RNA-DNA hybrids. This is 
followed by detection with a non-radioactive alkaline phosphatase- conjugated antibody 
catalysing the cleavage of a chemiluminescent substrate to emit light (Figure 2.1). A 
positive result is recorded when the relative light unit reading is equal to or greater than 
the mean values from positive controls (Poljak et ai., 1999; Clavel et ai., 1998). The 
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value of the positive control is generall y regarded as I, equivalent to Ipg/mll-IPV DNA 
(5000 copies) (poljak el al., 1999). This method, however, can not be used to identi lY the 
specific HPV genotypes but only to confirm the presence of HPV DNA from the above 
mentioned HPV types (Munoz el al., 2003). HC2 tests for high- and low-risk HPV types 
are commercially available. The HC2 high-risk HPV Test, which detects the high-risk 
HPV types mentioned above, is the one most commonly used. This is because medical 
govern ing bodies like the American Society for Colposcopy and Cervical Pathology 
(ASCCP) and American College of Obstetricians and Gynecologists (ACOG), among 
others, recommend testing for high-risk HPV types only for clinical purposes. This is due 
to the strong correlation of cervical disease to the high-risk HPV types (Wright el al. , 
2007). 
Ught emission on 
cleavage of substrate 
Alkaline phosphatase-
conjugated antibody 
Figure 2.1: Schematic ~presentation of th e HCl assay. 
Antibody captured onto 
wall ofmicrotitnl pl ate 
specific for DNA: RNA 
hybrids 
The use of HC2 gave fal se-negative results in some squamous cell carcinoma cases 
where high-ri sk HPV DNA was detected by PCR (Poljak el al., 1999; Seme el al .. 2006). 
The success of HC2 may be influenced by the severity of lesions and the viral load in the 
specimen: very low levels of HPV DNA may give a negative result. Despite this, the 
level of specificity for disease and sensiti vity for HPV DNA in HC2 assay is considered 
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adequate for use in cervical screening, and the specificity for disease is higher than that of 
PCR-based detection (Poljak et ai., 1999; Hesselink et ai., 2008). The sensitivity for HPV 
DNA of HC2 is comparable to that of PCR-based methods (Soderlund-Strand et aI., 
2005). 
2.2.2 HPV DNA testing by peR 
The majority of studies on HPV DNA detection have been done using PCR methods with 
consensus primers (Clifford et ai., 2006a). Many of these PCR methods used in HPV 
detection are 'in-house' developed, with a few which are commercially available. Most 
PCR based methods are followed by detection assays that allow for the identification of 
the specific HPV genotypes. These assay methods are mostly useful for detecting HPV in 
persistent infections; hence their ability to detect transient clinically irrelevant genotypes 
has to be as low as possible. This is critical in ensuring reliable results on specificity for 
disease and sensitivity for HPV DNA from high-risk persistent types responsible for high 
grade lesions (Hesselink et ai., 2008). Due to the occurrence of multiple infections in the 
population, the success of these methods is also evaluated on the ability to detect co-
infection with different HPV genotypes. In clinical settings it is important to detect the 
persistent infections in order to avoid non cost-effective follow-ups in women with 
normal cytology (Hesselink et ai., 2008). 
The major disadvantage of using PCR amplification is that there is competition for PCR 
primers when the samples have multiple HPV infections. This results in false-negative 
results in some cases (Lin et ai., 2008; Huang et ai., 2006). The sensitivity for HPV DNA 
of PCR detection methods varies greatly according to assay characteristics, type and 
quality of biological specimen and reagents. The sensitivity varies across the different 
'in-house' PCR methods (discussed in sections 2.2.2.1-3). The differences in results 
obtained arise due to the amplicon sizes and type of specimen as well as quality of DNA 
sample (Clifford et ai., 2006a). It is also possible that the differences are due to primer 
design methods, which may contribute to the sensitivity for HPV DNA for each primer 
set. To reduce the differences in the sensitivity of these PCR methods, there is a need to 
introduce standardised primers, methods, reagents and possibly reference samples for an 
internationally approved uniform method for HPV detection. However, this has not been 
implemented despite the observed differences in the 'in-house' detection methods 
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(Clifford et aI., 2006a). Currently, there are two PCR based systems that are 
commercially available; The Linear Array HPV Genotyping Test (Roche Diagnostics, 
Germany) and the INNO-Line probe assay (Innogenetics, Belgium). However, there is no 
mandate to use these in all HPV genotyping work. As a result, other different 'in-house' 
methods are also used, creating differences in results. This lack of uniformity in PCR is a 
major drawback when comparing results in epidemiological studies. Some of the 
commonly used PCR methods are detailed below. 
The primers used in PCR methods amplify a broad spectrum of HPV types in a single 
PCR reaction. Most HPV types are closely related; therefore primers have been designed 
to target the conserved LI gene of HPV genomes (Wheeler, 2002). These primers include 
MY09/11, PGMY09/11, GP5+/6+ and SPF1I2 or SPFlO, shown in Figure 2.2 (Manos et 
al., 1989; Gravitt et al., 2000; de Roda Husman et ai., 1995; Kleter et al., 1999). The 
PGMY09/11 primer set is a modification of MY09/11 primers (Gravitt et al., 2000). The 
modified primer set SPFlIGP6+ has also been used for detection ofHPV DNA (Huang et 
al., 2006). In Figure 2.2, the location of the various primer sets within the HPV genome 
with their respective PCR product sizes is shown. 
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Figure 2.2: Schematic representation of the locations of the different general primer sets (MY 0911 t, 
PGMY09111. GPS+f6+, SPFI I2 (SPF1, ) and SPFI /GP6+) on the HPV genome. The circular HPV DNA 
genome is represented by a single line, and the boxes show the positions of the early (E) and Iale (L) genes. 
The position of the different primer selS is indicated within the conserved Ll region. The amplicon sizes 
are also indicated. PGMY09/ 11 and MY09/ 11 have the same amplicon size, 450bp. The SPF lIG P6+ 
primers were modified from the GP5+/6+ and the SPFlfl primer sets. SPFII2 is also referred to as the 
SPFIO system (modified from KIeler et 01., 1999; Huang et 01., 2006). 
2.2.2.1 MY09JII and PGMY09JII primers 
The MY09JII primers amplify 27 HPV types, which were initi all y detected by the HPV 
dOl blot (Manos et al., 1989). HPV detection using the reverse li ne blot hybridisation was 
developed to improve simultaneous detection of multiple HPY types (Gravitt et al., 
1998). This detection method is detailed in section 2.3.3. The efficiency of amplification 
using the MY09/1 J primer set varies among the different HPV genotypes due to the 
degeneracy of the primers. Improved amplification of HPV types was achieved by the 
design of the PGMY0911 1 set. These eliminated degeneracies found in the MY09/ 11 set, 
thereby improving the sensitivity. specificity and reproducibility of the pe R (Gravitt el 
al., 2000; Caut"!e el al., 2002). PGMY09JII primers ampli fy 37 HPV types compared to 
the original 27 types amplified by the MY091l1 set. The commercial ly avai lable Roche 
Linear Array Hl'V Gena typi ng Test (Roche Diagnostics) incarpooated the PGMY09JII 
primers for HPV amplification. 
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2.2.2.2 GP5+/6+ primers 
The GP5+/6+ primers were designed as a modification to the GP5/6 primers (de Roda 
Husman et ai., 1995). The GP5/6 primers were elongated by three and five nucleotide 
bases, respectively, at the 3' terminals to result in the GP5+/6+ primers. The post-
amplification detection method is Southern hybridisation of amplicons to known HPV 
type-specific probes. These primers detect 22 HPV types with improved sensitivity 
compared to the GP5/6 primers (de Roda Husman et ai., 1995). Development of HPV 
detection assays led to the use of the GP5+/6+ peR enzyme immunoassay (EIA) (section 
2.2.2.2.1) and the reverse line blot hybridization (Jacobs et ai., 1997; van den Brule et ai., 
2002). Recent improvements on the GP5+/6+ primers resulted in the Broad-Spectrum 
GP5+/6+ (BSGP5+/6+) primers, which target 27 HPV types (Schmitt et ai., 2008). The 
primers were designed by alignment of 48 HPV genotypes. When compared to the 
GP5+/6+ primers, the BSGP5+/6+ set shows higher detection rates for some HPV types, 
for example, HPV 30, 39, 42,44,51-53,68, 73 and 82 (Schmitt et ai., 2008). 
2.2.2.2.1 En~me immunoassay 
After the peR with the GP5+/6+ primers, the amplicons are detected by hybridisation to 
digoxigenin (DIG)-labeled HPV -specific probes. This assay can also be used with 
amplicons generated by the SPF1I2 primers. The probes target a broad spectrum of high-
and low-risk HPV types and for each primer set the probe mixture solutions are different. 
The double-stranded amplicons are captured onto streptavidin-coated microtiter plate in 
the presence of hybridisation buffer. Denaturation of the captured amp Ii cons is achieved 
under alkaline conditions using NaOH (Kleter et ai., 1998). DIG-labeled HPV probes in 
hybridisation buffer are added to the microtiter plates containing the captured denatured 
amplicons. This allows hybridisation of the relevant HPV sequences to the specific HPV 
probes. The bound amplicons are detected by use of alkaline phosphatase-conjugated 
anti-DIG antibody and alkaline phosphatase substrate (p-Nitrophenyl phosphate) (Kleter 
et ai., 1998; Soderlund-Strand et ai., 2005). The reaction between alkaline phosphatase 
and its substrate is stopped with acid and the optical density (OD) readings are 
determined. The specimen is considered positive when the OD values are 2.5 times above 
the peR negative control (Kleter et ai., 1998). This assay detects the presence of HPV 
DNA from a total of 38 types without distinguishing the genotypes when used with 
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GP5+/6+ primer generated amplicons (Soderlund-Strand et ai., 2005; Hesselink et al., 
2008). 
2.2.2.3 SPF1I2 (SPFIO) 
These primers were designed in a similar target region of the L1 as the MY11 and GP5+ 
primers but targeting a shorter amplicon of 65bp (Kleter et ai., 1998). The post-
amplification detection methods are Southern hybridisation, EIA and the line probe 
assay, INNO-LiPA HPV prototype research assay (LiP A) (Kleter et ai., 1998; Kleter et 
ai., 1999). The EIA on amplicons generated by SPF112 primers detects a minimum of74 
types without distinguishing the HPV types. The LiP A detection system is similar to the 
reverse line blot hybridisation method, except that the primers used for HPV 
amplification prior to detection are the SPF1I2 set (Kleter et ai., 1999). The mixture of 
probes is also different to those in reverse line blot hybridisation: LiP A detects and 
distinguishes 25 HPV types. Among the 25 types identified by the LiP A, only three HPV 
types (30,57 and 74) are not detected by the reverse line hybridisation after amplification 
with PGMY09/11 primers. The LiP A can also be applied to amplicons generated by the 
MY09/11 primers (Kleter et ai., 1999). 
The SPF10 primers are reported to have increased sensitivity for HPV DNA compared to 
the GP5+/6+ set. As a result, they are capable of detecting HPV in specimens with low 
viral load (Kleter et aI., 1998). The increased sensitivity may be due to the short amplicon 
compared to the other PCR systems, since the kinetics of PCR generally favour short 
amplification products (Kleter et ai., 1999). When considering the detection of HPV in 
multiple infections, the PGMY09111 and the SPF multiple primers were shown to be 
more robust for HPV detection than the consensus MY09/11 primers (Kleter et ai., 1998). 
2.2.2.4 Type-specific primers 
In some cases, HPV type-specific primers have been used for the detection of HPV DNA. 
The primers are designed to amplify sequences within the E61E7 or L1 regions (Lin et ai., 
2008). The amplicons are subjected to agarose gel analysis and sequencing for HPV 
detection or detected using the EIA (Castle et ai., 2008). The main advantage of type-
specific PCR is the higher sensitivity for HPV DNA when compared to the other forms of 
PCR. However, the use of type-specific PCR assays alone in epidemiological studies is 
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impractical due to the diversity of anogenital HPV (Lin et ai., 2008). Therefore, the major 
disadvantage of this method in diagnostics is the need for parallel multiple PCR reactions 
to detect multiple HPV types in a single sample (Lin et ai., 2008). The process is labour 
intensive, especially when working with many samples as is the case in epidemiological 
studies. This method is most useful when used as an additional method, providing 
concrete and further evidence on the presence of particular HPV types. 
2.2.3 HPV distribution in South Africa 
When classified according to cervical disease, HPVs 52, 53, 16 and 35 were more 
common in 57 Cape Town women with LSIL while 53 women with HSIL were more 
commonly infected with types 16, 35 and 18 (Allan et aI., 2008). In contrast to these 
results, a study involving eight South African women with HSIL from Pretoria showed 
that the commonly prevalent types were HPV 35, 58 and 66 (Said et aI., 2009). In both 
these studies the Roche Linear Array HPV Genotyping Test was used for HPV detection. 
Therefore, the differences in HPV distribution pattern suggest that HPV distribution 
depends on lesion types and geographical location. A different pattern of HPV 
distribution was observed among women infected with HIV. In a study in Cape Town 
involving 37 women with HIV co-infection, HPV s 16, 45 and 66 were reported as the 
most common types among the HIV positive women (Marais et ai., 2008) (section 
1.6.3.1). When comparing with the results from 148 HIV positive women from 
Johannesburg, HPV 16 remained the most common type but HPV 45 was not one of the 
common genotypes (Firnhaber et ai., 2009). In addition to HPV 16, HPV 35, 51 and 66 
were also commonly detected in the Johannesburg population (Firnhaber et ai., 2009). 
Based on the differences in distribution among HIV positive and HIV negative women in 
South Africa, it is clear that HPV distribution pattern is influenced by HIV co-infection, 
geographic location and lesion types. 
In this chapter we evaluated the distribution of HPV types in 109 women from Cape 
Town who were also infected with HIV. The detection of HPV types infecting these 
women is crucial in the successful management of women infected with both HIV and 
HPV in South Africa since HIV infected women are reported to have an increased 
spectrum of HPV infection. It is also important for the development of prophylactic 
vaccines that include the most prevalent HPV types in HIV positive women. 
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2.3 Materials and Methods 
2.3.1 Study population 
The participants were recruited from an Anti-Retroviral (ARV) treatment clinic in Cape 
Town, South Africa. All the women in the study were eighteen years or older and the 
median age was 31 years (range 20-60 years). Informed consent was obtained from 
interested individuals to whom the details of the study were explained by the research 
nurse. Those who declined to participate were excluded from the study. Pregnant women, 
those who had had hysterectomies or were menstruating at the time of recruitment, were 
excluded from the study. A total of 109, both black and mixed race women, were 
involved in the study. All of the women had a Pap smear and those with HSIL were 
referred for colposcopy while the necessary follow-up was arranged for those with LSIL 
and ASCUS (Moodley et aI., 2009). Dr Jennifer Moodley was responsible for the 
recruitment of participants, Pap smear tests and also arranged for the necessary follow-up 
of women in this study. The study was approaved by the Human Ethics Committee at 
UCT in 2005 and the ethics approaval number is 06812005. 
2.3.2 DNA extraction 
Frozen cervical scrapings stored in Digene transport medium (Qiagen, Gaithersburg, 
USA) were thawed and DNA extraction performed using the MagNA Pure Compact 
Nucleic Acid Isolation Kit I (Roche Diagnostics, Mannheim, Germany). An automated 
extraction procedure was performed using a MagNA Pure Compact Instrument (Roche 
Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. Reagent 
cartridges, tip trays, elution tubes were placed into respective positions. The cervical 
samples (400~1) in 2ml tubes were loaded onto the sample tube rack. Sealed reagent 
cartridges containing the following reagents were used: Proteinase K, lysis buffer, 
magnetic glass particles (MGPs), isopropanol, wash buffer I and II, and elution buffer. 
Lysis buffer containing guanidine salts was used to lyse the cells. Proteinase K and the 
salts were also used to denature contaminating proteins, including nucleases. The DNA 
was then immobilized onto the MGPs and precipitated by the addition of isopropanol. 
Denatured proteins and other contaminants were removed by washing with buffers 
containing absolute ethanol. DNA was released from the beads at 80°C and eluted into 
2ml sterile tubes in 200 ~l of elution buffer (nuclease-free, sterilised water). Extracted 
DNA samples were stored at _20DC until further use. The use of nuclease-free sterile tips 
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and tubes eliminated contamination of DNA. The extraction was performed in an area 
dedicated for nucleic acid extraction only. 
2.3.3 peR amplification and HPV genotyping 
The Roche Linear Array HPV Genotyping Test (Roche Diagnostics, Mannheim, 
Germany) was used for the detection of HPV types in specimens. This test was used in 
this work because of its ability to distinguish specific HPV types within the high- and low 
risk groups, which is not possible with the HC2 test. Preparation of specimens for PCR 
was performed in a PCR -clean area to avoid contamination with amplified products. 
Amplification and detection ofHPV types were performed in the post-amplification area. 
DNA from clinical specimens was amplified according to the instructions of the HPV 
Genotyping and Detection Kit (Roche Diagnostics, Mannheim, Germany). The consensus 
primer set (PGMY09/11) designed in the conserved Ll region (Figure 2.2) was used to 
amplify a broad spectrum of 37 HPV genotypes in a single PCR. The reverse primers 
were biotin labeled at the 5' end to enable capture of the alkaline denatured amplicons 
onto streptavidin coated strips during post-amplification detection. The HPV master mix 
contained the PGMY09/11 primers to amplify HPV DNA from 37 types (450bp) and 
GH20IPC04 primers to amplify 268bp of the p-globulin gene: the human p-globulin gene 
was co-amplified in the same PCR reaction to assess sample adequacy, DNA extraction 
and amplification efficiency. The master mix also contained the enzymes AmpliTaq® 
Gold DNA polymerase and uracil-N-glycosylase (AmpErase); dNTPs including dUTPs. 
Master mix reagents in a total volume of 580lll were mixed with 1251ll of Magnesium 
chloride solution to give a working HPV master mix. The Mg2+ in solution was for 
enhanced activity of AmpliTaq® Gold DNA polymerase. This enzyme extended the 
primers bound to target DNA for the amplification of HPV and human DNA. The 
AmpErase enzyme eliminated carry-over contamination in PCR by catalysing destruction 
of amplicons containing dUTP. This ensured selective amplification of the required target 
DNA only. Fifty microlitres of DNA sample were added to 50lll aliquots of working 
HPV master mix and amplified in the amplification and detection area. 
PCR was performed under the following conditions: 50°C for 2 mm to activate 
AmpErase, 95°C for 9 min, followed by 40 cycles consisting of 95°C for 30 sec, 55°C for 
1 min, 72"C for 1 min and a final hold at 72°C for 5 min on an AB9700 machine (Applied 
Biosytems). The reaction was kept at 72°C until the addition of an alkaline denaturation 
38 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
solution from Linear Array Detection Kit (Roche Diagnostics, Mannheim, Germany) to 
denature the amplicons and AmpErase. Positive and negative controls from the kit were 
included in each amplification procedure. The positive control (50J..lI) had HPV 16 DNA 
and negative control (50ul) had no HPV DNA. The post-amplification detection of 37 
HPV types (HPV6, 11, 16, 18,26,31,33/35/52/58,39,40,42,45, 51, 53-56, 59, 61, 62, 
64, 66-73, 81-84, IS39 and CP6108) was carried out using Linear Array Detection Kit 
(Roche Diagnostics, Mannheim, Germany). IS39 is a subtype of HPV 82 and CP6108 is 
also known as HPV 89 (Clifford et ai., 2005). The denatured amplicon mixture (75J..ll) 
was transferred to appropriate wells in a typing tray containing hybridisation buffer and a 
single Linear Array HPV Genotyping Strip included in kit. The strip was coated with 
HPV and p-globulin oligonucleotide probes immobilized onto membrane. Each amplicon 
was hybridised to the strip at 53°C and was bound complementary probe with a matching 
sequence. There was one cross-reactive oligonucleotide probe that hybridised with HPV 
33,35,52 and 58. The Roche Linear Array HPV Genotyping test does not directly detect 
HPV 52, instead it combines a set of probes detecting HPV 33, 35, 52 and 58 as a group. 
The specimens that tested negative for HPV33, 35 and 58 individually but tested positive 
for the group were considered to be HPV 52 positive. Specimens that tested positive for 
the group and for HPV33, 35 and/or 58 had uncertain HPV 52 status although they were 
considered to be HPV 52 negative in this study. Following hybridisation and stringent 
washes with buffers containing SDS and sodium salts, streptavidin-horseradish 
peroxidase conjugate (SHPC) was added to the strip to bind to the biotin-labeled 
amplicons hybridised to the probes on strip. A substrate mixture of hydrogen peroxide 
(H202) and 3,3' ,5,5' -tetramethylbenzine (TMB) was added to each strip. The TMB 
substrate was oxidised to a blue colour by catalysis action of streptavidin-horseradish 
peroxidase in the presence of H202. The blue colour precipitated at probe positions and 
allowed for the reading of strips. 
2.4 Results 
HPV genotyping was performed in order to evaluate the distribution of HPV types in 109 
South African women infected with HIV. The high-risk types tested for were HPV 16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 59, 68, 73, 82, IS39 - a subtype of 82 and the probable 
high-risk HPV 26, 53 and 66. For analysis, the probable high-risk types were grouped 
under high-risk. The low-risk HPV 6, 11,40,42,43,44, 54, 61, 70, 72, 81 and 89 were 
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tested for. Other types ofundetennined risk were also tested for; HPV 62, 64, 67, 69, 71, 
83 and 84 (Section 1.5.1, Table 1.3). For the analysis of results, the seven 'unclassified' 
types were grouped with the low-risk types. The HPV types were shown as blue bands on 
HPV genotyping strips (Figure 2.2). 
From a population of 109 HIV positive women, 11% (121109) were found to be negative 
for HPV DNA (Table 2.1). A total of 37 genotypes were tested for, using the Roche 
Linear Array HPV Genotyping test and 95% (35/37) of the HPV types were detected in 
this population. All of the 18 high-risk HPV types mentioned above were present. Table 
2.1 shows the distribution ofHPV genotypes in this population. Among the 89% (97/109) 
who were HPV positive, 22% (21197) had a single HPV type and 78% (76/97) had at 
least two HPV types. In this study, 14% (15/109) and 15% (16/109) of the women had 
two and three HPV types, respectively (Table 2.2). Multiple HPV infections were 
common, with a median number of three HPV types per woman. The range of HPV types 
was 0-12. The most common HPV types among all women, in order of decreasing 
frequency, were HPV 61, 66, 53, 58, 18, 45, 70, 35, 16 and 51 (Table 2.1). 
A total of 98/109 women had a Pap smear result and 66% (65/98) of them had an 
abnonnal Pap smear result. Among these women the most common high-risk HPV types 
were 16, 58, 53, 51 (all at 29%), 66 (25%), 18 (22%) and 45 (20%). Among the women 
with abnonnal Pap smear, 10/98 (10%) had HSIL. The high-risk HPV types most 
prevalent in HSIL were HPV 45 (30%), 16,35,39,58 and 51 all at 30%, as well as types 
66, 18, 31 and 33 with 20% prevalence rate (Moodley et ai., 2009). 
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Figure 2.2: Roche Linea r Array HPV ge notyping test results fOT 10 clinical sp«!cimens, each st rip 
represents a specim en except for the negat ive and positive cont rol st r ips. All samples showed both the 
!}-globulin high and low for the results to be validated. The HPV types in each specimen are shown by the 
blue bands. As an example in this sel of resu lts, specimen HH01 5 (indicated by the red arrow) had. from 
lell to right, HPV 16, 39, 40, 45, 52, 53, 55, 59, 70, 71, 81 , and 84. The intensity of the band is directly 
propon ional to the viral load in specimen. For spt!(:imen HHOl5, bands for HPV 16 and 39 were more 
intense than the others, therefore it was assumed that there weTC higher viral loads for these two than the 
other types. The HPV types for spt!(:imen HH020 are indicated as HPV 6, 18, 53, 55 and 58. HPV 52 
presence in this sample could not be ascenained; therefore the appearance ofa band on the group types was 
inferred to indicate presence of HPV 58. 
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Table 2.1: Genotyping results of KJV positive women from a clinic in Cape Town, South Africa. 
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61 I 09 
I Due to multiple infections, some individuals had both high- and low-risk types therefore number 
represents individuals with either high-risk types only or high- and low-risk HPV types. The probable high-
risk types were included in the high-risk category. 10 Women with only the low-risk HPV types. ~ 1539 is a 
subtype of HPV 82 (Cli fford el 0/., 2005). Both 1$39 and HPV 82 were detected in one specimen H.PV 
CP6 108 is also known as HPV cand89 (Clifford el 0/., 2005). ' cand ' refers to HPV type identified by 
cloning and characterisation of PCR ampiicons (de Villiers el 0/ .. 2004). For fun.hcr analysis, 1$39 and 
HPV 82 were recorded as HPV 82 and CP61 08 was recorded as HPV 89. 
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2.4.1 Low-risk HPV types 
The low-risk HPV 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and 89 (CP61 08) were tested 
for. The other types tested for were of undetermined risk and these were HPV 62, 64, 67, 
69, 71, 83 and 84 (Section 1.5.1, Table 1.3). These two groups were considered as low-
risk types in this study. HPV 61 occurred most frequently in this population, with a 
prevalence rate of 24% (26/109). The other low-risk types detected in the study, in order 
of decreasing frequency, were HPV 70, 62, 54, 55, 83, 84, 89, 81, 71, 72, 40, 6, 69, 11, 
42, and 67, as illustrated in Figure 2.3. Of all the low-risk HPV types tested for, 94% 
(17/18) of them were detected. No samples were positive for HPV 64. 
2.4.2 High-risk HPV types 
The following HPV types in the Roche Linear Array HPV genotyping test were 
considered to be high-risk: 16, 18,26,31,33,35,39,45,51,52,53,56,58,59,66,68, 73 
and 82 (section 1.5.1, Table 1.3). HPV 66 is classified as a probable high-risk type 
therefore it was grouped together with the high-risk types, as were HPV 26 and 53. All of 
these types were detected in these women as shown in Figure 2.3. HPV 66 accounted for 
the highest prevalence among the high-risk HPV types (18%). The common HPV types 
in the high-risk category were 66 (18%), 53 and 58 (17%), 18 and 45 (16%), 35 (15%) 
and 16 (14%) (Table 2.1). 
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Figure 2.3: The prevalence of low- an d high-risk HPV types IIImong 109 HIV positive women at a 
clinic in Cape Town. The probable high-risk types 26, 53 and 66 were included among the high-risk HPV 
types. The total percentages were more than 100 because somc women were counted more than once due to 
multiple in fections. 
Table 2.2: Summary of the prevalence of HPV and multiple infection in HlV 
positive women (0=109) in Cape Town. 
Number of ISDecimens 
HPVtypes N % 
0 12 I I 
1 21 19 
2 15 14 
3 16 15 
4 11 10 
5 8 7 
6 11 10 
7 2 2 
8 6 6 
9 3 3 
10 1 I 
11 2 2 
12 1 I 
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2.5 Discussion 
From this study, we detennined that 89% (97/109) of the women were infected with one 
or more HPV types (Table 2.1). The method used for detection of HPV DNA has a major 
impact on the perceived diversity of HPV identified in a population. The use of 
PGMY09/11 primers and reverse line blot hybridisation method has been shown to be an 
effective way to detect HPV DNA in cervical specimens (Gravitt et al., 2000). 
The prevalence pattern observed in this group is similar to that observed in a study in 
Uganda (Banura et al., 2008) on HIV positive women. Both studies confinn that there is 
a high rate of HPV infection among HIV positive women. The Ugandan study showed 
that HIV positive women have higher HPV infection rates as well as increased multiple 
infections than the HIV negative women. The number of HIV positive women in that 
study was 82/950 and 88% (72/82) of HIV positive women were HPV DNA positive 
compared to 73% (635/868) among the HIV negative women (Banura et a!., 2008). Levi 
and colleagues in Brazil also observed a high HPV prevalence of 98% (2041208) among 
HIV positive women (Levi et al., 2002). Similarly, the HPV prevalence in our study was 
89% (97/109), but HIV negative women were not included in our study. MUltiple 
infections accounted for 78% (76/97) of all HPV positive women compared to only 22% 
(21197) women with single infections. In the Ugandan study, 65% (53/82) of the HIV 
positive women had multiple infections, which was an increase in multiple infections 
from 37% (19/868) among the HIV negative women (Banura et a!., 2008). This clearly 
indicates that HIV positive women have more multiple infections than the HIV negative 
women. Most women in our study (82%, 89/109) were infected with at least one high-
risk HPV type and 7% (8/109) of women had only low-risk HPV types (Table 2.1). When 
considering that high-risk HPV types can lead to cervical disease or neoplasia, co-
infection with high-risk types in HIV positive women might explain why HIV positive 
women are more susceptible to developing cervical disease. The high rate of infection 
with high-risk HPV types noted in our study increases the risk of developing cervical 
neoplasia among HIV positive women. 
HIV infected women are more likely to shed HPV over a long period of time than HIV 
negative women (Baseman and Koutsky, 2005). This implies that HPV detection in these 
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women is also higher than in the HIV negative women (Banura et ai., 2008; Singh et ai., 
2009). In a study of 208 HIV positive women in Brazil, 98% (204) of them were positive 
for one or more HPV types (Levi et ai., 2002). This may suggest that HIV positive 
women would have at least one HPV type detected. In our study, 12% (11/109) of the 
women had no HPV DNA detected. While this result may be a true reflection of HPV 
status in these women, it is also possible that HPV DNA detection was hindered by HPV 
DNA integration. Integration of HPV DNA in HSIL and cervical cancer can disrupt the 
primer binding sequences within Ll ORF or can lead to loss of the Ll ORF, therefore 
leading to a negative result by PCR (Clavel et aI., 1998; Walboomers et ai., 1999). 
A negative HPV DNA result can also be caused by latency. Latent HPV DNA can exist 
at very low copy numbers that are difficult to detect even with sensitive methods like 
PCR. Latency of HPV DNA is not fully understood. Therefore, there is still need for 
further investigation into how long latency lasts, and when or under what conditions is 
HPV DNA re-activated to detectable levels (Schiffman and Kjaer, 2003). HPV latency 
could result in reactivation of latent HPV DNA in HIV infected individuals, thus 
explaining the wide range of HPV types detected. 
In contrast to other epidemiological studies in a worldwide general population, HPV 16 
was not the most common HPV type identified among HIV positive women (with or 
without cervical abnormalities) in our study. HPV types other than 16 have been detected 
commonly among women with HIV infection. This HPV distribution pattern was 
observed in studies in Brazil, America, Uganda and Italy (Levi et ai., 2002; Luque et ai., 
2006; Banura et ai., 2008; Tanzi et aI., 2009). Among all the women in our study, HPV 
16 prevalence was only 14% (15/109). HPV 61 (24%, 26/109), a low-risk type, was 
found to be the most prevalent type among women with normal and abnormal cytology 
(Table 2.1). Tanzi and co-workers (2009) also reported in their study on HIV infected 
individuals in Italy that HPV 61, together with 6 and 11, were common HPV types 
among all HIV positive women in that population (Tanzi et ai., 2009). This suggested 
that low-risk types may persist in HIV positive women. While this may seem 
extraordinary in HIV negative individuals, it is not surprising that low-risk infections 
tend to persist in HIV positive women. This is due to the low HPV clearance in HIV 
infected women as a result of reduced HPV -specific immune response (Palefsky, 2006). 
The high-risk HPV types 56, 52, 53 and 58 were frequently detected in women with HIV 
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infection (Luque et al., 2006; Banura et aI., 2008). In agreement with results from these 
and other studies in South Africa, our study also observed an increase in other high-risk 
HPV types other than HPV 16. Overall, HPV 66, 58, 53, 45, 18 and 35, in order of 
decreasing frequency, were frequently observed in our study. All of these HPV types 
have been reported in similar studies in South Africa (Marais et al., 2008, Firnhaber et 
ai., 2009), although the order of frequency was different across studies. 
Due to immunosuppression, HIV positive individuals are susceptible to frequent and 
persistent HPV infections and the immune system may not be able to clear low-risk HPV 
infections (Chirenje, 2005; Frisch et al., 2000). As a result, HIV positive individuals 
experience an increased rate of progression to CIN2/3 and the low-risk types may also 
lead to high grade lesions in severely immunosuppressed women (Luque et al., 1999; 
Frisch et al., 2000; Clifford et al., 2006b). This was observed from a meta-analysis on 
HPV infection among HIV positive women from different countries, in which the low-
risk HPV types 11 and 61 were more frequently detected in some of the HIV infected 
women with HSIL. No high-risk HPV types were detected in 9% (16/185) of the women 
with HIV infection who had HSIL (Clifford et al., 2006b). Therefore, this gives 
possibility that low-risk HPV types can cause cervical disease in immunocompromised 
women. 
When considering cervical disease, the most common HPV types in women with 
abnormal cytology in this study were HPV 16,58,53,51,66, 18 and 45 (Moodley et al., 
2009). Among these women the most common high-risk HPV types were 16,58,53,51 
(all at 29%), 66 (25%), 18 (22%) and 45 (20%). The prevalence ofHPV 16 among these 
women did not dominate over the other types as the prevalence was the same as for some 
other high-risk types (Moodley et al., 2009). This is in agreement with the general trend 
that HPV 16 is not predominantly prevalent in HIV infected women. These results were 
comparable to another study in Cape Town where HPV 45,66 and 16 were also found to 
be common in HIV infected women (Marais et al., 2008). In yet other studies in Uganda 
and Rwanda, HPV 52,58,51 and 16 were common in HIV infected women with disease 
(Blossom et al., 2007; Singh et al., 2009). Among these, HPV 52 was the only type that 
was not reported among the common HPV types in our study. 
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From the results in different countries, it is clear that the spectrum and prevalence of 
HPV is different in HIV positive women from different geographic locations. However, 
differences in the prevalence rates can also be due to the sample sizes and methods used 
in genotyping. For HPV genotyping, Singh and co-workers (2009) used the SPF10 
primers followed by Southern hybridisation and dot blot hybridisation (Singh et al., 
2009). Blossom and colleagues (2007) used the PGMY09/11 primers followed by reverse 
line blot hybridisation for detection of 27 HPV types (Blossom et al., 2007). In our study, 
HPV genotyping was performed with the Roche Linear Array HPV Genotyping test 
(section 2.3.2), which does not distinguish HPV 52 from HPV 33, 35 and 58. The 
population sizes ofHIV infected women in Ugandan and Cape Town studies were small 
(37/106 and 371115, respectively) compared to our study of 109 HIV positive women. 
Singh and colleagues' study had 710/936 HIV positive women, a larger population 
compared to our study in 109 women. Therefore the differences in the genotyping 
methods and sample sizes could have contributed to the differences in HPV 52 patterns in 
the different studies. On the other hand, it is also entirely possible that there are different 
genotypes in the populations under study. 
The prevalence of HPV 52 (9%) in our study may not give a true reflection of its 
prevalence among HIV women as it was grouped with HPV types 33, 35 and 58. Because 
HPV 52 was scored positive when neither of these specific types was present 
individually, co-infection with HPV 52 was possible for each specimen that was positive 
for the group as well the other types. As a result, the actual prevalence of HPV 52 could 
be higher than the observed 9% (10/109). This underestimates the existence of this type 
in a population. A further analysis of the specimens presumed to be HPV 52 positive by 
use of type 52 specific primers could improve the detection of this genotype and therefore 
give more reliable information on its prevalence. The use of one detection method for 
HPV detection in prevalence studies may result in the underestimation of the prevalence 
of some HPV types in the population as opposed to two or more methods. 
This study showed that there is a wide range of HPV types infecting HIV positive 
women. A total of 35 low- and high-risk HPV types were identified. There were frequent 
multiple infections detected, with 70% (76/109) of the women showing at least two HPV 
types. The median HPV types per woman was three, ranging from 0-12 types. 
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3 Introduction 
3.1 HPV variants 
HPV s are divided into genera, species, types, subtypes and variants. Members of different 
genera (alpha-, beta- and gamma-papillomavirus) share less than 60% similarity in 
nucleotide sequence in the capsid protein L1 ORF. Same species groups share between 
60-70% similarity in the sequence of the same gene. HPV types within a species are 
defmed by 71-89% nucleotide sequence similarity within the L1 ORF (IARC, 2007). 
Subtypes share between 90-98% homology with prototype sequence (Hazard et aI., 
2007). This means that subtypes differ from the prototype sequence by 2-10% within the 
L1 ORF. Variants show 98-99% homology in DNA sequence within the same region, 
which is less than 2% difference from the prototype in the nucleotide coding region of L 1 
protein (de Villiers et aI., 2004). The difference in the L1 ORF of prototype and variant 
sequences can be in one or more nucleotide bases. These point mutations may either be 
silent or result in a change in an amino acid when compared to the protein sequence of 
the prototype HPV sequence (Tu et al., 2006). 
Nucleic acid sequencing data from previous studies show that there are a number of 
naturally occurring 'variants' of certain HPV types. Most studies have been done on the 
intratypic variants of HPV 16 since it is one of the most commonly occurring high-risk 
HPV s. HPV 16 variants seem to be more common than variants of other HPV types and 
are normally associated with particular ethnic groups (Hazard et aI., 2007), and 
geographical regions (Kurvinen et aI., 2000). While some authors argue that subtypes 
appear to be rare or virtually absent compared to variants, Hazard and others report that 
HPV subtypes are common (Bernard, 2005; Hazard et ai., 2007). According to Hazard 
and colleagues (2007), about 47 subtypes/putative subtypes of HPV exist. These are 
classified into 30 subtypes within the genus beta-papillomavirus, ten within genus 
gamma-papillomavirus and seven subtypes within the genus alpha-papillomavirus 
(Hazard et ai., 2007). 
The distribution of HPV 16 variants across five continents is grouped according to their 
location: Asian-American (AA) found in the Central and South America; African (At) in 
African continent; Asian (A) predominant in South East Asia and lastly European (E)-
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found in all regions except Africa (Berumen et al., 2001). Some variants are more often 
associated with cervical cancer than others. In fact, Berumen and others (2001) reported 
that infections with the AA variants had an increased risk of developing cervical cancer 
compared to those with E variants (Berumen et aI., 2001). Tu and colleagues (2006) 
claim that some Af variants are associated with increased risk of invasive cervical cancer 
compared to the E variants in South African women (Tu et al., 2006). In contrast to this, 
Tornesello and colleagues (2000), in their study among Ugandan males, argue that there 
is no evidence to suggest different oncogenic activity in the Af-l HPV 16 variants as 
compared to the European variants. However, they do report that there is enhanced 
transcription activity in the LCR of Af-l variants as compared to that of E variants 
(Tornesello et ai., 2000). Interestingly, after comparing work that had been done 
previously on other variants in USA, Brazil, Costa Rica, China, it was shown that 
association with cervical cancer depends on the geographical location (Tu et al., 2006). 
Whether or not a certain variant is associated with increased risk for cervical cancer 
seems to depend on the possibility that specific populations have developed a certain 
level of resistance to the transforming potential of variants found commonly in their area 
(Tu et al., 2006). It is also possible that the absence of immunologic interactions is the 
major reason for the reduced evolutionary restraints, therefore allowing adaptation of new 
HPV variants to different types of differentiated epithelia (zur Hausen, 2000). 
Genetic variation has been identified by amplification and sequencing of regions within 
the E6 and E7 genes and the LCR. Nucleotide differences within these regions indicate a 
variant (Bernard, 2005). HPV 16 variants have been identified in the E7, Ll, L2, E5 and 
E2 genes as well as E6 and LCR. The sequence variations or mutations in these regions 
have the potential to modify the function of the encoded protein (Berumen et al., 2001) or 
affect the binding affinity of transcription factors when they occur in the LCR. Mutations 
in the binding site (s) of negative transcription factor Yin-Van factor 1 (YYl) were 
shown to increase expression levels of E61E7. Furthermore, point mutations in HPV 16 
and 18 LCR enhancer regions and upstream of it result in increased transcription activity 
(Tornesello et al., 2000). 
Virus replication and transcription of E61E7 proteins are regulated by E2 proteins binding 
to regions within the LCR. The LCR also regulates transcription through a number of cis-
responsive elements (Tornesello et aI., 2000). These response elements include the 
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steroid responsive elements, particularly the glucocorticoid response element (GRE). The 
GREs of some HPVs can function as progesterone response elements (PREs), and 
therefore allow progesterone levels to play a significant role in HPV -induced 
transformation. It has been demonstrated that several glucocorticoid-regulated promoters 
within the LCR can be induced by progesterone (Chan et ai., 1989). High progesterone 
levels occur during pregnancy, thus explaining why high parity is considered a risk 
factor. 
The LCR is divided into three distinct sections comprising of the 5', central and 3' 
segments (Figure 3.1), all of which have different functions. The 5' end has a high A + T 
content (approx 85%) and contains the negative regulatory element (NRE) as well as the 
nuclear matrix attachment region (MAR) (Tomesello et ai., 2000). The MAR seems to be 
conserved within most genital HPV s, indicating a significant role in the virus life cycle. 
The NRE acts at the level of mRNA stability whereas the MAR represses the expression 
of the E61E7. The central segment of LCR acts as an epithelial specific transcription 
enhancer (Tomesello et ai., 2000). This enhancer region acts as binding region for 
cellular transcription factors such as NF-I, NF-IL6, AP-l, YYl, TEF-l and Oct-I, whose 
binding has been proven in in vitro experiments. The 3' segment houses the origin of 
replication and the E61E7 promoter, p97 (Tomesello et ai., 2000, Stiinkel et ai., 2000). 
The p97 promoter of HPV 16 is regulated through E2 function, binding of transcription 
factors to the enhancer region and the GRE. While the binding of most of the 
transcription factors generally stimulates the promoter activity, binding of NF-IL6 and 
YYl to the enhancer region can also down-regulate the promoter activity (Kurvinen et 
ai.,2000). 
5'end 3' end 
P97 NRE'MARregion Central enhancer region TATA 
I ~ t, 7100 7200 7300 7400 7500 7600 7700 7~ 7900 on 
Figure 3.1: Schematic representation of HPV 16 LCR. Transcription factors including Oct-I, NF-I, 
YYI, and API bind in the enhancer region in addition to other sites along the LCR (Kammer et aI, 2000; 
Tomesello et aI., 2000). 
52 
I 
90 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The regulation of viral/cellular genes is critical in determining the outcome of HPV 
infection as it may lead to cervical cancer. Therefore, any nucleotide changes within HPV 
enhancer/promoter regions where transcription factors bind may have an impact on 
disease progression (Tomesello et at., 2000). Sequence changes within the LCR and 
other HPV genes are associated with the oncogenic potential of the infecting HPV. As an 
example, the mutation within the YYl binding site is known to increase transcription of 
the E61E7 oncogenes (Pande et at., 2008). Studies on the HPV 16 genome revealed high 
polymorphism in LCR, resulting in variant identification. In these studies, the prototype 
HPV 16 genome was identified as an E variant (Kammer et at., 2002). A good number of 
studies have been done on HPV 16 variants in other countries, including Finland, Brazil, 
Mexico and India, but few studies have looked at the HPV 16 variants in African women. 
Although a lot of work has been done to identify the HPV genotypes in HIV infected 
women, there is limited information on studies of HPV 16 variants in these women. In a 
study on HPV genotypes and HPV 16 variants in HIV positive women in Italy, 
Tomesello and colleagues (2008) identified only the E and Af-2 variants. In that study, 
HPV 16 variants were identified from HIV positive and HIV negative women with 
normal cytology and cervical neoplasia (Tomesello et ai., 2008). 
The primary focus of work reported in this chapter was to identify HPV 16 variants in 
HIV infected individuals with varying disease severity. From the results in Chapter 2, it 
was observed that 15/109 (14%) of the individuals were infected with HPV 16. HPV 16 
has been identified to have at least five variants which tend to occur according to 
geographical locations and some of which have been claimed to be more virulent than 
others. Therefore, HPV 16 variants in our sample set of 15 women were investigated. 
3.2 Materials and Methods 
3.2.1 PCR amplification ofHPV 16 LCR 
Fifteen specimens positive for HPV 16 were identified using the Roche Linear Array 
HPV Genotyping test as described earlier (Chapter 2, Table 2.1). Primers specific to HPV 
16 LCR were designed to target the LCR. The primers are shown in Table 3.1. PCR mix 
was set up in a total volume of 50~1 as follows: 20pmol of each primer, 200~M dNTP 
mixture, I.3U of high fidelity Pfu DNA polymerase enzyme (Promega, Madison, USA), 
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IX Buffer with magnesium salt (Promega, Madison, USA) to enhance enzyme activity 
and 3fll DNA. The dNTP mixture contained the nucleotides (dCTP, dTTP, dATP and 
dGTP) for the extension of primers. The high-fidelity enzyme was used to reduce 
replication error-rate during the amplification of LCR. The amplification protocol was 
followed according to Kurvinen et al (2000): initial denaturation at 940 C for 10 minutes, 
35 cycles consisting of 94
0 
C for 1 minute, 62
0 
C for 1 minute and 72
0 
C for 2 minutes to 
allow for primer extension. Final extension was at 72
0 
C for 10 minutes for the final 
elongation of primers. 
Table 3.1: Primers used in the amplification ofHPV 16 (Kurvinen et al., 2000) 
Primer name Sequence and length of primers Position Length (bp) 
HPV16LCRF 5' -CCTCATCT ACCTCTACAACTGCT AAACGC-3' (29) 7108-7136 
HPV16LCRR 5' -CGTCGCAGT AACTGTTGCTTGCAGTACACAC-3' 222-192 
(31) 
3.2.2 Cloning and sequencing 
The cloning and sequencing of LCR amplicons was performed in order to compare 
sequence variation with the prototype HPV 16. The amplicons were electrophoresed on 
1 % agarose gel as detailed in Appendix Aiii. The amplicons were excised from gel and 
purified as outlined in Appendix A v. The purified PCR amplicons of LCR were cloned 
using a pGEM®-T Easy cloning system (Promega, Madison, USA) (Appendix Avi) to 
facilitate sequencing using Sanger's dideoxy chain termination method (Appendix Aviii). 
The cloned fragments were transformed into E.coli DHa cells as outlined in Appendix 
A vii. Single colonies of clones were grown in LB (Appendix Ai) and DNA was isolated 
from bacterial cultures according to protocol in Appendix Aii. At least two clones from 
each specimen were selected for sequencing. Each clone was sequenced twice to 
eliminate PCR and sequencing artefacts, using the primers in Table 3.1. Sequencing was 
performed at Macrogen, Korea, using the Sanger chain termination method. The 
sequences were compared to the reference HPV 16 (GenBank accession number K02718) 
for the detection of nucleotide variation. Differences in nucleotide sequence were 
recorded with respect to their position in genome. 
54 
1028 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
------ ----------------------------------------------
3.3 Results 
3.3.1 PCR amplification of HPV 16 LCR 
The LCR was amplified fTom HPV 16 positive isolates (n= 15) that were identified using 
the Roche Linear Array HPV Genotyping test. The full LCR was amplified from rour 
samples as shown in Figure 3.2, to give a 1028bp fragment. The same amplicon size 
(1028bp) was obtained from the other eleven specimens HHOI5, HHOI6, HH038, 
HH049, HH054, HH055, HH065, HH069, HH082, HH095 and HH097. All amplicons 
were cloned and sequenced for investigation of sequence variation within the LCR. 
tOOOObp __ 
IOOObp __ 
500bp ------+ 
250bp --
negati~ MarkeS" positive HHOO3 HHOIO HH012 HH076 f-DiIOS 
-
-
-I028bp 
figure 3.2: Representative aga rose gel elecl ropheresis after amplification of HPV 16 L.CR (rom 
clinical spcc:imens. This agarose gel shows amplified LCR from four specimens that were HPV 16 
positive. Negative lane shows a no DNA negative control and lane HHI08 was a DNA negative control. 
Specimen HHlO8 was HPV 16 negati ve. The posit ive lane was a positive DNA control from specimen 
HHOI 5. 
3.3.2 Sequence analysis of LCR 
Sequencing of all cloned amplicons was perfonned in order to identi fy basepair changes 
within the LCR in comparison to the prototype HPV 16. The original HPV 16 sequence 
published (GenBank accession number K02718) had sequencing errors, which were later 
corrected. These corrections were within the LCR at nucleotide positions 7432·7433 
(CG), which was corrected to CCG and at position 7861 where nucleotide (nt) A was 
deleted as part of the correction. The corrections resulted in a shift in the numbering of 
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nucleotide positions by two or three bases. The numbering used in this analysis was 
according to the original sequence. The prototype sequence used in this study was HPV 
16 GenBank accession number K02718. 
The nucleotide base differences for the variants identified are shown in Table 3.2. 
Analysis of HPV 16 variants in these women showed that both European and African 
variants can exist within the same individual (Table 3.2). 
A total of 36 different point mutations were detected within the LCR at 35 different 
positions. Both the transition and transversion mutations were observed; 44% transition 
mutations while 56% were transversion point mutations. There were common nt changes 
noted at 16 positions across most of the specimens. These were at positions G 7191 T, 
A7231C, G7385C, G7432A, A7482C, G7486A, G7518A, C7666T, C7686A, C7761T, 
C7783T, G7823A, G7831T, A7834C, A7836G, and C31T (Table 3.2). Two different 
transversion mutations at same nt position (A 7231 C, A 7231 T) were observed. The 
number of nt changes in each isolate ranged from 1-17. The most common mutation was 
a transition point mutation G7518A (highlighted in Table 3.2), which was detected in 
73% (11/15) of the specimens. Five nt changes that have not been reported before were 
also observed. These were A7230G, C7550A, T7865C, C7874A, and G59A. Among 
these, A7230G and C7874A were detected in the Af-l variants and the other mutations 
were observed in Af-2 variants. 
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Table 3.2: Nucleotide sequence changes within HPV 16 LCR 
GRE E2 YYl API NF-I YYI YYI 
? 7 ? 7 ! ! 7 ! ! 7 7 7 7 7 ? ! ? ! ! ! 7 ! ? ? 7 7 7 ? 7 U ... pOlltlon In HPII16R 
~ ~ ~ 
2 
~ ~ ~ ~ ~ ~ 4 ~ : ~ ~ : : ~ 7 8 8 8 2 5 8 ~ 3 3 7 5 5 5 1 1 3 6 3 1 4 6 5 4 1 3 9 3 3 Total-
Ua .. In HP1I16R •• quence 
A T G A A A T e G G A A G e A e e T A e e G C G G A A T e e c G C A 35 
Variant SampltldenUty 
HH003 • T T e A e A A T A T T A T e G T 17 
b ,c T T e A e A T A T T A T e G T 16 
Af-2 HH003 • T T e A e A T A T T A T e G T A 17 
HH010 
.. C 0 
E HH010 h T 1 
Af-1 HH012 .. d,., r T G G A A A T T T A T C 13 
E HH015 c T T T 4 
A HH015 d T T 3 
Af-2 HH016 .. I, e C A e A T A T T e A T C G T 16 
E HH038 
.. c 0 
Af-2 HH049 .. b, ... 1 T T C e A e A T A T T A T C G T 17 
Af-2 HH054 • T C C A C A T A T T A T C G e T 17 
E HH054 b, c, f"g 0 
Af-2 HH054 J T e C A C A T A T T A T C G T 16 
Af-2 HH055 b, t, r, 9 G T C C A T C A T T T A T e G T 17 
E HH065 at b, c.d, _ A 1 
AA HH069 .,b, 1 T e C T e A T A e T T T 13 
Af-2 HH069 c,. T C C T C A e T T T A T e G T 16 
HH076 • T e e A T C A e T T T A T C G T 17 
Af-2 HH076 c,d,e, f T e e A C A e T T T A T C G T 16 
HH082 
.. e..,1 T e e A e A T A T T A T C G T 16 
E HH082 d 0 
Af-2 HH095 .. Co d, e, f T e e A C A T A T T A T C G T 16 
E HH097 
.. e.g,1 0 
Single nucleotide base differences within the LCR of HPV 16 variants in comparison to the prototype sequence HPVI6R, GenBank accession number K02718. Sample 
identity refers to the specimen number, and the letters a-j refer to the different cloned sequences per specimen (isolates) analysed per specimen. Total refers to the total 
number of mutations in each analysed clone. The red highlighted base pair position indicates the position where the most frequent base-pair change among all the isolates. 
Some of the common binding regions within the LCR are indicated at the respective base positions. 
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Some of the mutations were observed in transcription factor binding regions of the LCR. 
G7385C mutation was observed in the GRE region in 9 (60%) isolates while the mutation 
A7455T, in 3 isolates (20%), occurred in the E2 binding site. The transition mutation 
C7761 T was detected upstream of the NFl transcription factor binding site while 
T7711A occurred within its binding site. The mutations G7518A, C7783T and G7823A 
were found within the YY1 binding site. A transversion mutation, A 7633C, which is 
located at the API binding site, was observed in 2/15 (13%) of the specimens. Other 
mutations located in binding sites include C7550A, C7666T, C7686T, A7726C, G7796C, 
C7815T, G7831T, A7834C A7836G and C31T (Tanzi et ai., 2009; Pande et ai., 2008). 
3.3.3 Phylogenetic classification ofHPV 16 variants 
A phylogenetic analysis of the cloned sequences was performed to identify the variants 
present in each specimen. The sequences were compared to those of the known variants 
of HPV 16. The phylogenetic classification of the variants found in the specimens is 
shown in Figure 3.3. The E variants were present in 7/15 (47%) of the specimens listed in 
Table 3.3. In addition to the E variants, the A, AA, Af-1 and Af-2 type variants were also 
identified. Some specimens had more than one variant and multiple infections were noted 
in 4/15 (20%) of the specimens (HH015, HH054, HH069 and HH082). In two of these 
specimens (HH054 and HH082), the E variant was present together with Af-2 variant 
(Figure 3.3). In the third specimen (HH069), AA and Af-2 variants were detected and one 
specimen (HH015) was co-infected with A and E variants as shown in Figure 3.3. 
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Table 3.3: The HPV 16 variants identified among the specimens according to 
phylogenetic distribution. 
Variant type Specimen(s) Frequency (%) ofvariants (n=15) 
AA HH069a 7 (1/15) 
Af-l HHOl2 7 (1115) 
Af-2 HH003, HHOI6, HH049*, HH054*a, HH055, HH069c, 60 (9/15) 
HH076, HH082a, HH095 
E HHOlO*, HHOI5c, HH038, HH054b, HH065, HH082d, 47 (7/15) 
HH097 
A HHOl5d 7 (1/15) 
AA- Asian American, Af-I - African type I, Af-2 - African type 2, E - European, A - Asian. Letters a-d, 
after specimen number indicate different cloned sequences per specimen (isolates) within the same 
specimen or sample as shown in Table 3.2. * indicates a specimen with unique mutation patterns within the 
same variant when compared to the other isolates from other specimens. Due to multiple variant infections, 
some specimens were recorded more than once, therefore the percentages exceed 100%. 
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'-------------------82a 
'---------------------95 
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,-------- 55b 
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76a 
76c 
'-------------------------69a 
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'--------- 15c 
,-----------------65a 
,--------------- 10c 
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,---------- 54f 
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HPV16R Icr 
97 
Figure 3.3: Identification of HPV 16 variants by phylogenetic analysis of isolates. The evolutionary 
history of HPV 16 variants was inferred using the Neighbor-Joining method (Saitou and Nei, 1987), based 
on the nucleotide sequence of the LCR. The evolutionary distances were computed using the Maximum 
Composite Likelihood method (Tamura et aI., 2004). All positions containing gaps and missing data were 
eliminated from the dataset. Phylogenetic analysis was conducted in MEGA4 (Tamura et ai., 2007). HPV 
16R \cr, HPV 16 Af-l and Af-2, HPV 16 East-Asian and HPV 16 Asian-Amer represent GenBank 
sequences of LCR from the E, Af-l and Af-2, A and AA variants, respectively. The GenBank accession 
numbers for the variants were K02718, AF472508, AF472509, AF534061 and AF402678, respectively. 
The sequences analysed are indicated by specimen number followed by a letter between a-j. 
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3.4 Discussion 
The identification and analysis of HPV 16 variants found in specimens from HIV positive 
women showed the presence of both E and non-E variants. All the non-E variants were 
identified; these were the A, AA and Af variants. Most of the observed mutations have 
been previously reported, with the exception of five nucleotide changes that have not 
been reported. These were observed in isolates which belong to the Af-1 and Af-2 
variants. 
Co-infection with multiple HPV 16 variants has been reported in previous variant studies 
(Stewart et al., 1996) and this was also noted in our study. This suggested sexual mixing 
behaviour between different populations. Migration of host populations explains the 
distribution of variants across countries (Stewart et al., 1996; Pande et al., 2008). The 
presence of both E and non-E variants in our study is evidence of this. The majority of 
variants in our study were the Af variants (67%, 10/15 specimens), with the Af-2 type 
accounting for 90% (9/10) of Af variants. In comparison, the E variants were reported in 
only 47% (7/15) of the specimens. The observed prevalence of variants in this study 
conforms to the belief that specific variants often cluster in their geographic location and 
dominate by continent and lineage (Yamada et al., 1997; Bernard et al., 2006). Migration 
of host, founder effects and co-evolution of HPV may have contributed an important role 
to effect this distribution (Stewart et al., 1996; Yamada et al., 1997). 
Although both E and non-E variants could be identified based on previously reported 
mutations in the isolates, some uncommon mutations within specific isolates were 
observed. These often occurred as unique mutations within single specimen, some of 
which have not been reported previously. An example of this was specimen HH049, an 
Af-2 variant, which exhibited a unique transversion mutation A7153T in all the four 
sequenced isolates (Table 3.2). Some uncommon, possibly new mutations within the 
LCR were observed. These mutations were A7230G, C7550A, T7865C, C7874A, and 
G59A. The occurrence of these previously unreported mutations may suggest that the 
point mutations are very frequent within LCR region. As a result, the sequence variations 
arising from these mutations increase genomic diversity of HPV 16. 
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Some variants may have high oncogenic potential. The detection of mutations within and 
upstream of transcription factor binding sites could be responsible for increasing the 
oncogenic potential of the variants (Pande et al., 2008). A particular example in this 
study was the commonly observed mutation G7518A (73%, 11/15) in the YYl binding 
site, which increases the p97 promoter activity. This increases transcription of the 
oncoproteins E6 and E7 and potentially increases transformation of cells. This would 
modify the biological properties of the virus, potentially resulting in cervical disease in 
individuals habouring these viruses (Kammer et al., 2000; Tomesello et ai., 2004; Tanzi 
et al., 2009). This mutation occurred among the Af-2 variants and was absent in the E 
variants except in one isolate (HHOI5), which had the most unique mutations. 
There are several YYl binding sites that are affected by the mutations observed in these 
variants. Those mutations occurring within the YYl binding site are found in the majority 
of cervical cancer patients throughout the world. Mutations in this site are absent from 
non-cancer cases therefore they probably playa major role in carcinogenesis (Alencar et 
al., 2007; Pande et al., 2008). Other mutations that occur at lower frequency in 
populations include those in the Oct! binding site. Nucleotide changes in this region 
result in the down-regulation of HPV expression (Pande et al., 2008). Although these 
mutations have been shown to increase disease severity in different ways, the host's 
genetic component and possibly also HLA haplotypes influence development of invasive 
cancer. 
A mutation in the GRE region (G7385C) was one of the common sites of variation within 
the LCR as it was detected in 60% (9/15) of the specimens, all of which are Af-2 
variants. The occurrence of GREIPRE within the LCR has a significant impact on the 
ability of HPV to transform cells and result in malignancy. The discovery of these 
regulatory elements showed the critical role played by the LCR in determining the 
outcome of an HPV infection (Chan et ai., 1989). Burk and colleagues (2003) observed 
that mutations in the GRE region result in HPV 16 variants responding differently to 
hormonal changes and impacting differently on oncogenicity of variants. The 
mechanisms by which this occurs still remain to be elucidated (Burk et ai., 2003). A 
mutation in the API binding site (A7633C) within the Af-2 variants was also observed 
and is known to down-regulate HPV expression (Pande et al., 2008). Most of the 
mutations whose effects are well characterised and known to increase risk of cervical 
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disease/cancer were observed among the Af variants. This may suggest that the claims 
that Af variants are associated with disease may be true. 
Due to lack of clinical data, it was not possible to further analyze the particular variants 
in relation to disease severity among the HIV infected women as the disease status on 
specific individuals with HPV 16 was not available. However, it was clear that HPV 16 
was one of the most common types among women with abnormal Pap smears (29%) 
(Moodley et ai, 2009). Although there are claims that Af variants are associated with 
increased risk of developing cervical neoplasia/cancer, Tu and colleagues (2006) reported 
that the Af variants were not associated with increased risk of neoplasia. Their argument 
was based on results from their study on HPV 16 variants in South African women whose 
HIV status was unknown (Tu et al., 2006). Therefore, such an investigation would prove 
helpful in understanding the risk associated with HPV variants affecting South African 
women infected with HIV. 
In this study, the variants were determined from polymorphism of the LCR since it is 
considered to be the best region for variant identification (Stewart et al., 1996). The high 
level of sequence variation reported in this study proves high genomic diversity among 
HPV 16 genome and it is possible that this pattern may be shared by other genotypes that 
may be less prevalent in populations. Similar sequence variations observed in HPV 39 
sequences may suggest that more HPV types have similar variation patterns. 
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4 Introduction 
In Chapter 2, HIV infected women were found to display a wide spectrum of HPV types. 
The observed diversity of HPV types may suggest that there could be more mucosal HPV 
types that could still be identified if a different approach is used. When considering the 
high number of multiple infections observed, it is possible to conclude that the detection 
method used in Chapter 2 may not include as many mucosal HPV types as there exist in 
HIV infected women, due to HIV positive women being known to have higher rates of 
HPV infection compared to their HIV negative counterparts (Banura et ai., 2008). 
Therefore, more HPV types are likely to infect these women than those incorporated in 
and detected by the Roche Linear Array HPV genotyping test. 
In addition to the PCR-based detection methods, other methods that have been utilised in 
HPV genotyping include pyrosequencing. HPV genotyping of clinical specimens through 
pyrosequencing of PCR products with multiple HPV -specific and general primers has 
been successful (Gharizadeh et ai., 2001; Gharizadeh et ai., 2005). In this chapter, the use 
of pyrosequencing technique on genomic DNA to detect HPV types was explored. 
Pyrosequencing was performed following rolling-circle DNA amplification (RCA) of 
circular HPV DNA. The multiply-primed sequence non-specific RCA procedure was 
used together with pyrosequencing method to detect HPV types in one of the clinical 
speClmens. 
Rolling-circle replication is a replication mechanism used by certain circular DNA 
genomes such as plasmids and viruses (Rector et ai., 2004). During rolling-circle 
replication (RCR) the DNA is unwound and DNA polymerase synthesises a sequence 
complementary to the template DNA strand. This process can be mimicked in vitro, for a 
technique known as RCA, through the use of random hexamers and bacteriophage <D29 
DNA polymerases (Rector et ai., 2004). RCA has been applied in the identification of 
novel types or strains of viruses with circular DNA genomes. The discovery of novel 
viruses used to be done through Southern blot hybridisation, which allowed identification 
based on homology between related sequences. This means that there had to be prior 
knowledge of the sequence of at least one virus type. However, this only allowed 
determination of part of the genome (Rector et ai., 2004). The complete genome was then 
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elucidated by an inverse PCR method. Alternatively, amplified genomic DNA was 
digested with restriction enzymes and cloned before sequencing (Rector et ai., 2004). 
When the RCA method was discovered, genomic DNA could be analysed for new 
divergent viruses in a sequence non-specific manner by directly sequencing RCA 
products. The ability of RCA reactions to maintain sequence specificity of DNA during 
amplification led to their application in genotyping and in mutation detection studies 
(Demidov, 2005). Therefore, RCA was used in our study to amplify HPV genomes prior 
to sequencing to detect the HPV genotypes in one specimen. 
In this study, RCA coupled with pyrosequencing was used for genotyping HPV in an 
individual co-infected with HIV. The results were compared to those of the Roche Linear 
Array HPV Genotyping test for the same specimen, HH015, with 12 HPV types. This 
specimen was chosen as it had the highest multiple HPV infection (as detected by the 
genotyping test) compared to the others. DNA from that specimen only was 
pyrosequenced due to time and budget limitations. The specimen was investigated for 
other existing but undetected, new and recombinant HPV types. Recombination was 
investigated by cloning and sequencing of complete HPV genome. The persistence of 
multiple HPV s can promote recombination between the different HPV types. South 
Africa has a high prevalence rate of HIV and with increased HPV infections in these 
women, investigation of the possibility of recombination events in HPV genomes among 
South African women was necessary. 
4.1 Materials and Methods 
4.1.1 Rolling-circle amplification of DNA for pyrosequencing 
HPV circular DNA from one sample infected with 12 HPV types and co-infected with 
HIV (HH015) was amplified by RCA using the Illustra™ TempliPhi 100 Kit (Amersham 
Biosciences, GE Healthcare, UK). The reaction was performed according to 
manufacturer's instructions. One microlitre of genomic DNA was mixed with 5~1 of 
sample buffer in a 0.2ml tube. The sample buffer contained exonuclease-protected 
random hexamers. The mixture was heated at 95°C for 3 minutes to denature the ds DNA 
and cooled on ice. A premix of the TempliPhi enzyme mix (0.2~l) and TempliPhi 
reaction buffer (5 ~l) was prepared in a separate tube. The enzyme mix contained the <1>29 
DNA polymerase, extra dNTPs and extra hexamers in 50% glycerol. The TempliPhi 
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reaction buffer contained dNTPs and salts for enzyme activity. Five microlitres of the 
premix were added to the cooled sample and mixed by vortexing. The reaction was 
incubated at 30°C for 18 hours on an AB9700 machine (Applied Biosystems). 
Ampli fication was initiated by the hybridisation of exonuclease-protected random 
hexamer primers to the circular DNA. The procedure continued in a chain reaction where 
the kinetics of multiple hybridisation, primer-extension and strand displacement occurred 
as ill ustrated in Figure 4.1. Due to the strong displacement capabi li ty of bacteriophage 
<D29 DNA polymerase, strand displacement occurred when the enzyme reached a 
downstream extended primer (Rector el 01. , 200S; Demidov. 200S). This allowed for 
amplification of the nucleotide sequences by several magni tudes, yielding several 
complementary tandem repeats of an original DNA circle. The result was a distinct set of 
concatemers of ds I-IPV DNA. After the reaction, the mixture was incubated at 6S·C for 
10 minutes to inactivate bacteriophage (1)29 DNA polymerase. Two microlitres of sample 
were electrophoresed on 0.8% agarose gel as outlined in Appendix Aiii . The rest of 
sample was stored at _20°C unti l further use in subsequent reactions. 
Circular 
DNA 
genome 
Random primers 
3lUleal to DNA 
B c 
Primer extension as DNA 
is replicated 
,'" 
D 
Str311d displacement 
E 
Linear DNA 
genome 
: / 
--
-.= 
== 
f 
Figu re 4. 1 A-F: S4: hematic diagra m or rolling-c ircle a mplification in circula r genomes. Random 
hexamers annealed to DNA template at mu lt iple sites (B). The enzyme extended each of the primers until it 
reaches another downSlTeam extended primer (C). Bacleriopage (b29 DNA polymerase allowed strand 
displacement to occur (D). The displaced single strand acts as an available template and more hexamers 
annealed to it for further extension (E). Continued extension and strand displacement resulted in 
amplification to give double-stmnded DNA (E). Restriction endonuclease digestion using enzymes with 
single recognition site within the circular DNA genomes yields linear ds HPV DNA (F) (modified from 
Rector et a/. , 2004). 
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4.1.2 HPV genotyping by pyrosequencing 
This technique was used to detect HPV genotypes in one specimen. HH01 5. The genomic 
DNA was randomly fTagmented by nebulisation, to create a library of between 300-
800bp fragments and shan adaptor molecules were attached to the DNA library (Figure 
4.2). 
a 
DNA hbrary on 
beads layered wIth d 
'~"' ..... '{: 
ss-DNA wllll adapter 
molecules at ends 
b 
EmulSlon PeR 
Bead wltb se\'eral 
Figure 4.2 : Sample prepara tion for pyrosequ encing on the 454 Genome Sequencer (GS) FLXTM 
system (Roche Diagnostics). DNA was randomly fragmen ted to create a library of between 300-800bp 
fragments. Adapter molecules were attached to the single-stranded fragments generated by fragmentation 
of genomic DNA and bound to beads (a). The beads were captured in droplets ora PCR-reaction-mixturt-
in-Qil emulsion before clonal amplification (b). Each library bead was loaded into a single well (c) and 
DNA library beads were layered with enzyme beads (d) before being loaded on a 454 PicoTiterPlate device 
(Modified from Margulies el 01., 2005). 
The adaptor molecules were used in subsequent purification, amplification and 
sequencing reactions (Droege and Hill , 2008). The DNA fragments were captured onto 
beads under conditions promoting onl y a single·stranded DNA molecule per bead, and 
clonally amplified. This generated millions of unique DNA templates per bead as shown 
in Figure 4.2c (Margulies el 01., 2005; Droege and Hill , 2008). The generated DNA 
library beads were added to the DNA Bead Incubation Mix contain ing exonuclease 
deficient (exo) Klenow DNA polymerase 1 (DNA polymerase I). Each bead was 
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deposited by centrifugation into a 44~m picotitre well on a picotiter device. The library 
beads were layered with Enzyme Beads (with sulfurylase and luciferase enzymes) onto a 
picotiter device. The device was mounted onto the GS FLXTM instrument where 
sequencing was performed in a number of cycles (Droege and Hill , 2008; Margulies ef 
aI., 2005). During DNA sequencing, a single base was incorporated by DNA polymerase 
I to extend the bound DNA template (Figure 4.3). The synthesis of each base resulted in 
the release of an inorganic pyrophosphate (PPi) during each nucleotide flow cycle. The 
PPi was converted to ATP by sulfurylase enzyme in a reaction that generated enough 
energy for oxidation of luciferin by luciferase (Figure 4.3). The luciferin produced light 
that was quantitated by a charge-coupled device (CCD) camera to determine the number 
of bases incorporated (Bentley, 2006; Ronaghi , 2001). The camera simultaneously 
captured images from different wells that contained template-carrying beads where a 
nucleotide had been incorporated in each cycle of nucleotide flow. Each cycle of 
nucleotide flow was fo llowed by a wash with apyrase enzyme to remove all 
unincorporated nucleot ides before the next fl ow started. This generated several base reads 
which were analysed on the de novo assembler (Margulies el aJ., 2005). 
(I' 
ONAC_Boad 
oootlllnlng mUUons 01 
_04 ... "11/. 
donaI~_ 
AlP 
Figure 4.3: Pyrosequencing using the 454 sequencing tcchnology of scq ucncing-by-synthesis. The four 
nucleotide bases, ACGT, were cycled several times through the sequencer and each base was added one at 
a lime to the template, in yellow. The adapter molecules are shown in green. A chem iluminescent signal 
was generated during the cycle and processed to determine base sequence (Taken from Droege and Hill, 
2008). 
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Pyrosequencing was perfonned at Inqaba Biotech, Pretoria. The sequence results were 
assembled using the de novo sequence assembler, NewblerAssembler at Inqaba Biotech. 
The assembler showed overlapping regions of the same HPV types by alignment of 
generated reads. This allowed for the creation of overlaps between reads and 
subsequently larger sequences from overlapping short sequences. Assembled sequences 
were searched against the HPV database using the Basic Local Alignment Search Tool 
(BLASTN) from the National Center for Biotechnology Infonnation (NCBI) 
(www.ncbi.nlm.nih.gov). The sequences that did not result in known HPV sequences by 
BLASTN were also searched for potential HPV ORFs, using BLASTX. 
4.1.3 Restriction enzyme analysis and cloning of HPV genome to detect 
recombination 
The restriction enzyme analysis was perfonned in order to facilitate cloning and 
subsequent sequencing of full length HPV genome and detect recombination events. 
Circular DNA from HH015 amplified by rolling-circle mechanism was analysed with 
restriction enzymes EcoRl, BglI and BamBI to identify the restriction patterns for each 
enzyme. The enzymes were selected based theoretical analysis using DNAMAN software 
(version 5.2.9) to identify enzymes with one restriction site within full length genomes of 
HPV types detected in sample HHOI5. The RCA product was analysed with the 
mentioned restriction enzymes as outlined in Appendix Aiv. 
The amplified DNA was digested with EcoRI as outlined in Appendix Aiv. The digestion 
mix was ligated into a dephosphorylated EcoRI digested pUC19 vector (Appendix Avi). 
The ligation products were transfonned into E. coli DH5a cells as in Appendix A vii. The 
transfonned cells were plated onto Luria-Bertani agar (LA) plates with ampicillin for 
selection of clones. Single colonies of E. coli from LA plates were inoculated into Luria-
Bertani broths (LB) to replicate cloned DNA. The LA plates and LB were prepared as in 
Appendix Ai and all growth of E. coli was at 37°C for 18 hours. Bacterial cultures were 
incubated at the same temperature on a shaker. DNA isolation from bacterial cultures was 
perfonned as in Appendix Aii. 
70 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
4.1.4 Sequencing and analysis 
The cloned genome was sequenced usmg the Sanger chain termination method 
(Appendix A viii) at Macrogen, Korea. This was done to identify recombinant regions 
within the HPV genome. Sequencing was achieved by primer-walking, initially using 
standard M13 primers shown in Appendix -Bii. Subsequent primers were designed from 
the generated sequence and used for sequencing (Appendix C). This was repeated until 
the whole genome was sequenced. The sequenced regions were analysed using 
DNAMAN software version 5.2.9 and searched in the NCB! database using BLAST 
facility (www.ncbi.nlm.nih.govlblast). The full genome was analysed for recombination. 
4.2 Results 
4.2.1 Rolling circle amplification of DNA 
Circular DNA amplification by RCA was performed to non-specifically increase circular 
DNA concentration for subsequent pyrosequencing reactions. DNA was amplified by 
extension of several hexamer primers, hybridised to ssDNA molecules, by <1>29 DNA 
polymerases. This resulted in linear amplification of DNA to give several thousands of 
copies of the original DNA in solution. The amplification process enriched the DNA 
sample for the pyrosequencing reaction by increasing the copy number of the different 
HPV types in HH015 sample. Figure 4.4 shows the agarose gel electrophoresis of RCA 
product. The RCA product was further analysed by sequencing on the 454 OS FLXTM 
and the Sanger chain termination method. 
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negative 
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DNA 
marker 
10 OOObp ---l.. 
8000bp 
IOOObp---__ , 
pUC I 9 
DNA HHOl5 
Figure 4.4: Gel el«trophoresis of roliin g-circJe a mplification product of DNA from HHOIS on O.S-/_ 
agarose gel. The plasmid, pUCI9, DNA was used as a positive control in the reaction and the negative 
control was water. Amplified DNA was electrophoresed as a smear, lanes HHOl5 and pUC 19. 
Pyrosequencing and the Roche Linear Array I-IPV genotyping test were used to compare 
the I-IPV types identified by the two methods. The Roche Linear Array HPV Genotyping 
test identified 12 HPV types, shown in Figure 4.5. Pyrosequenci ng identified seven types; 
HPV 16, 30,39, 40, 56, 74 and 86. 
, 
= 
! 
• • 
" 
~ ­;: E 
== 
Figure 4.5: The Roche Linea r Array HPV Genotyping test on speci men HHOIS. The HPV types 
identified in the specimen are shown above. The darker bands indicate hi gher viral load in comparison with 
other bands. HPV 39 DNA appeared to be the most abundant in the specimen . 
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4.2.2 HPV detection by pyrosequencing 
Pyrosequencing on DNA from specimen HI-I01 5 was performed to detect HPV types in 
specimen and compare to the types detected by the Roche Linear Array HPV genotyping 
test A total of 13 128 reads were generated from pyrosequencing. Each read consisted of 
between 200·300 bases. The reads were assembled into 976 sequences. A summary of the 
data from the NCBI database search on all the 13128 reads is shown in Figure 4.6. The 
reads showed homology to DNA from the fo llowing organisms; humans, HPV, bacteria, 
Pan troglodytes, Pongo abelii, Mus musculus and Macaca mu/ata among others. The 
number of reads fo r HPV was only 0.19% of the total reads. The majority of the reads 
had high homology to human DNA. Therefore, most of the reads belonged to human 
DNA sequences, with 1.21 % or lotaJ 13 128 reads. 
1.4 
1.2 -
'" 1 "0
= .. 0.8 ... .. 
'" = 0.6 . > 
'-0 
~ 
= 0.4 
0.2 D 0 --
Human cellular Prevolella Human No Hits Pan troglodytes 
intermedia papiUomavirus 
Figure 4.6: Summary ofsigoificant BLAST sea rch results of base reads generated by pyrosequencing 
using the 454 GS FLXTM system, from the NCB I database. The search was conducted by using BLAST 
on all the reads, 0= 13128. Most of the reads represented DNA of human origin. 
A total of 976 sequences were obtained from the de novo assembly of all 131 28 reads 
generated from the pyrosequencing. The sequences were searched in the NCB I database 
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using BLASTN and 23 (2%) sequences were found to be from known HPV types. The 
specific HPV type for each of the 24 sequences is listed in Table 4.1. The other 
organisms which were identified from the database search of the sequences include 
Prevotella intermedia, or a relative: this is a bacterium infecting the mouth and is 
responsible for periodontitis (Finegold, 1995), and this was identified from one sequence 
of length 3087 bases. 85% of this sequence (query coverage) had 85% homology to the 
bacterial sequence. This significant homology result suggests the presence of this 
organism in the total DNA extracted from HH015. Bacteroides fragilis nucleotide 
sequence was also identified, showing 88% query coverage and 72% homology. Three 
other sequences (2 x 241 and 133 bases) showed high homology (100%) to a Human 
endogenous retrovirus K (HERV K), a normal part of the human genome in most 
individuals and does not cause disease (Boller et al., 1993). 
Some of the sequences had high homology (97%) across the entire 241 base sequence 
(100% query coverage) to the pan troglodytes DNA when searched in the NCBI database. 
These were considered to be sequence similarities between human DNA and Pan 
troglodytes DNA since humans and chimpanzees share common ancestry. Most of the 
other organisms were identified from sequence lengths of 1 00-400bp. The sequences were 
short and their coverage in the database varied from 8-88% from Mus musculus and 
Macaca mulata. These were considered to be related to human DNA but not present in 
sample. Several other sequences (48/976, 5%) had no significant homology to any 
organisms in the database. The size of these sequences ranged from 98-1356 bases, with a 
median length of 241 bases. No new HPV types were detected and obviously 
recombinant HPV sequences were absent. All the sequences that did not yield significant 
homology (5%, 48/976) from the nucleotide database were searched against the protein 
database in NCBI for potential HPV ORFs. Among these sequences, no HPV proteins 
were detected from the database search. 
The seven HPV types identified were 16, 30, 39, 40, 56, 74 and 86. While some HPV 
types were identified from one sequence, other HPV types identified were represented by 
more than one sequence, as shown by the sequenced regions in Figure 4.7. The coverage 
of the sequences was between 98-100% (Table 4.1) except for two sequences, one for 
HPV 16 and HPV 74, which had 88% and 71% coverage, respectively. This was 
probably a result ofthe programme used to assemble sequences. The similaritylhomology 
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of all nucleotide sequences to regions of their respective HPV s in the database ranged 
from 97-100% (Table 4.1). 
The number of full-length genome sequences (-7.9kb) ofHPV from this sequencing was 
limited to two. These were HPV 39 and HPV 40 (Figure 4.7d and e). The other HPV 
genomes were fragmented, with long regions missing, for example HPV 30 (Figure 4.7t). 
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Table 4.1: Summary ofHPV sequence identity from BLASTN 
(www.ncbi.nlm.nih.gov/blast) 
Length HPV GenBank Query cover % 
(bp) Identity accession no. (%) identity 
208 HPV30 X74474 99 99 
192 HPV30 X74474 100 98 
137 HPV30 X74474 100 100 
334 HPV16 K02718 100 100 
145 HPV 16 K02718 100 97 
950 HPV 16 K02718 88 99 
2229 HPV16 K02718 99 99 
2744 HPV 16 K02718 100 99 
1505 HPV 16 K02718 100 99 
241 HPV56 X74483 100 98 
184 HPV56 X74483 100 100 
221 HPV56 EF177181 99 99 
184 HPV56 X74483 99 99 
228 HPV56 EF177179 100 100 
HPV56 X74483 92 100 
231 HPV74 AF436130 99 97 
HPV74 U40822 99 96 
218 HPV74 U40822 (cds) 100 99 
HPV74 AF436130 100 95 
672 HPV74 AF436130 99 98 
HPV74 U40822 99 94 
122 HPV74 AF436130 100 99 
419 HPV74 AF436130 98 98 
HPV74 U40822 98 93 
241 HPV74 AF436130 71 97 
241 HPV86 AF349909 100 96 
7831 HPV39 M62849 100 99 
1896 HPV40 X74478 100 99 
6058 HPV40 X74478 100 99 
Region in genome 
7388-7183 
487-677 
5839-5703 
315-648 
245-389 
7904-7172 
644-2872 
2860-5606 
5618-7124 
5840-5600 
4358-4541 
1523-1303 
1522-1302 
7268-7496 
7280-7491 
699-473 
3649-3420 
1354-1136 
6285-6067 
5597-6267 
666-1336 
2800-2921 
6624-7037 
1692-2103 
322-493 
7983-7777,32-1 
7833-2673,2672-1 
2738-839 
7909-2764, 914-1 
HPV sequences as identified from the NCB I database through BLAST. HPV 39 was the only HPV type 
with a continuous whole genome sequence. The two HPV 40 sequences give an almost full genome 
sequence, with 73 bases missing to complete the genome. HPV 16 had six fragmented sequences, all of 
which show that they were from different variants of HPV 16 as indicated by the GenBank accession 
numbers. HPV 56 had five sequences, all from different regions of this type. HPV 74 had six different 
sequences of varying lengths, which belong to either the HPV 74 subtype AEIO (AF436130) or the HPV 
74 coding domain sequence (U40822). Only one 241 base sequence resulted in HPV cand86 (cand refers to 
candidate HPV type, which was cloned and characterised from PCR products (de Villiers et al., 2004). This 
will be referred to as HPV 86). Query cover defmes the length (%) of the sequence being searched in 
database against the resulting sequence from the NCBI database. For example, 99% query cover for 208 
bases sequence indicates that 99% of 208 bases were aligned to the sequence found in database, in this 
case, HPV 30. 
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• 1 •• • 
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c 
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-7983 
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SOObp HPV39 ~ 
7833 
e 
SOObp HPY40 
~ 
- 7909 
r 
500bp HPV30 
'-' 
• • • 7852 
g 
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'-' 
• • 
-
• 7844 
Figure 4.7 : A schematic re presentation of the sequen ced regions of the HPV types identified by 
pyroscqucncing. 
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Some of the HPV types detected by pyrosequencing were not detected by the Roche 
Linear Array l-IPV Genotyping test. The HPV types detected by each of these methods 
are listed in Table 4.2 below, highlighting the differences and similari ties in the types 
identified by each method. 
Table 4.2: Detection methods used for HPV types in specimen HHOJS and the types 
identified in each method. 
Detection method HPV types detected 
Roche Linear Array HPV genotyping 16, 39, 40,45, 52,53, 55, 59, 70, 71,8 1, 84 
lest 
Pyrosequencing with the 454 Genome 16, 30, 39, 40, 56,74, 86 
Sequencing FU(TM system 
The types common in both methods are highlighted in red. 
4.2.3 Detection of recorn bination in npv 
Restriction enzyme analysis was perfonned on the RCA product of DNA from specimen 
HHO 15 to facilitate cloning of complete Iinearised HPV genomes. This specimen had 12 
differen t HPV types (Figure 4.5). The restriction enzymes that digested the HPV types 
present in HHO 15 were Bgll, BamHi and EeaR1. The types digested by each of these 
enzymes are indicated in Table 4.3 . The restriction pattern for each enzyme is illustrated 
in Figure 4.8. 
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Table 4.3: Restriction enzymes that digested HPV types present in specimen HH015 
Restriction enzyme 
No. of enzyme sites and enzyme di2estion sites 
HPVtype EcoRI BamHI BglI 
16 (2) 6818, 7453 (1) 6150 
30· (1) 1483 (1) 6511 
39 (1) 6824 (2) 1473,4738 (1) 6572 
40 (3)6661,6957,7089 (1) 4409 
45 (2) 920, 6933 
52 (2) 111,5093 (1) 7559 
53 (1) 6830 (1) 6098 
55 (2) 37, 2170 (2) 574, 5032 
56- [(3)2360,7449,7491 (1) 5521 
59 (1) 69 
70 (1) 3849 (2) 5847, 6900 
74- (1) 4920 (1)6511 
81 (1) 4758 (4) 1649,2086,2948,6796 
84 (1)7888 (1) 4465 
86- (3)250,6519,6983 (1) 4443 
a _ HPV types identified by sequencing on 454 OS FLXTM system but not the Roche Linear Array HPV 
Oenotyping test. HPV 71 was not digested by the selected enzymes. 
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Figure 4.8: Gel electrophoresis of RCA product of DNA from sp«imen H.HOI5. The RCA product 
migrated through the agarose gel as a smear (undigested RCA product). The DNA was digested with BgII. 
BamHI and EcoRI. The negative control was a no DNA sample. The positive control, pUC 19, was digested 
with £CoRI. Digestion of RCA product with 8g11 and £coRI gave one fragment-8000bp, while restriction 
analysis with BamHI gave three fragmcnls: 8000bp, 4200bp and 3800bp. 
The enzyme EcoRl was selected for the cloning of complete HPV genomes for the 
detection of recombination based on restriction pattern observed when DNA was digested 
(Figure 4.8). EcoR I generated one 8000bp size fragment and digested more types 
compared to BglI. Digestion of DNA with BamHI resulted in three fragments (Figure 
4.8). According to the digestion pattern in Table 4.3, EcoRl digested less HPY types in 
specimen HHOl5 than BamHl (Table 4.3). The digestion pattern for EcoRl shown in 
Figure 4.8 showed that HPY 16, 52, 55 and 56 did not sbow any bands as expected since 
tbey have more than one EeoRl site (Table 4.3). HPY 81 DNA digested with 8gII did not 
show any bands in the agarose gel (Figure 4.8). The EeoRl digested RCA product was 
cloned into pUC 19 vector and two clones (15.2 and 15.3) were selected for sequencing to 
identify regions of recombination in HPY genome. 
The EcoRllinearised and cloned HPY genome was initially sequenced with M 13 forward 
and reverse primers. Analyses of the sequences from both clones (15.2 and 15.3) 
identified the cloned genome as HPV 39 (GenBank accession number M62849). as 
shown in Figure 4.9 and 4.10. After the complete genome was sequenced (Figure 4.11), 
the short sequences were aligned to give one complete HPV 39 sequence. All the 
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sequences had between 98-100% homology to HPY 39. No recombination regions were 
detected although several point mutations were prescnt within the sequence (Figure 4.12). 
The analysis of the same DNA sample using a different restriction enzyme could not be 
completed within the time fiame of this project, hence no further clones could be 
sequenced. 
>r fit Y.~ l:~;. _ H!!':l~ ;:=:. ':lpllc:.a":U-JS o""...!s 
:.e;i;-;:.=1 ~J3 
!cc:~ = :~53 t: ~ :, (:2-5 1. EJq:~C':. = c, ~ 
::!~:'I:lue, = H: / €42 Wi-\ I . Ga~, = :' H2 ( : ~ 1 
S!an.:i=P!Js / pllu 
" 
Figurt 4.9: BLASTN sta rch resu lt from a sequtnct gtnuatoo by M 13 forward primtr. showing 
100·/. homo logy to HPV 39. Subjeet represents Human papillomavirus ORFs sequence, also known as 
HPV39 and the query sequence is shown in the top line. 
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Figure 4. 10: Bl..AST N search result from a sequence gene rated by M 13 reverse primer, showing 99-;. 
homology to HPV 39. Query sequence shows the sequence submitted for search in database while the 
subjecl is the identi fied organ ism, HPV 39. 
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Figure 4. 11 : Partial sequences of HPY 39 generated by prim er-wa lking. Sequencing was initiated by 
M 13 primers in the L I region at the restriction site of EcoRI. 
HPVJ9 AAATGCAACAGATACAGGTTCAGACCTGGCAGACTTTATTGATGATTCCACAGATATTTGTGTACAGGCAGAGCGTGAGA 1120 
15 . 2 -------------------------t------------------------------------------------------ 1120 
15 . 3 -------------------------t------------------------------------------------------ 1120 
HPVJ9 AGATGATGCAACCGGTACCTGCTGGTCATATTTCGATAATTATATGAGAAATGCATTAGATGGGTATGCAATAAGTTTAG 2560 
15 . 2 ----------------------------------a--------------------------------------------- 2560 
15 . 3 ------------------------------------------------------------------------ - ------- 2560 
HPV39 CCGCCGCCGTCTCGAAAGCGACCTCGACAGTGTGCAGTCACAGAGCCCACTGAGCCCGACGGAGTGTCCCTGGACCATCT 3600 
15.2 ----------------------------------------------------------------------- - - ----- - - 3600 
15 . 3 ---------------------------------------------------------------t---------------- 3600 
HPV39 TAACAACCCACTCCACAGTAACAGTACAGGCCACAACACAAGACGGTACCTCAGTTGTGGTAACACTACGCCTATAATAC 3680 
15 . 2 ---------------------------------------------------------------- - --------------- 3680 
15 . 3 -----------------------------------------------------t---------------c---------- 3680 
HPV39 ATTTAAAAGGTGACAAAAATGGTTTAAAATGTTTAAGATATAGACTACAAAAATATGACACATTGTTTGAAAATATTTCA 3760 
15 . 2 ------------------------------------a -----4----------------------------------- - - 3760 
15 . 3 ------------------------------------a -----4------------------------------------- 3760 
HPV39 TGTACCTGGeATTGGATACGGGGTAAGGGAACCAAAAACGCTGGeATATTAACTGTTACATATGCCACAGAGTCACAACG 3840 
15 . 2 ---------------------------------------------------------------------3---- - ----- 3840 
15 . 3 ---------------------------------------------------------------------a- - -------- 3840 
HPV39 GGATATTGTGTATGTATATTGTATACATACTACATAGATGATATTATTGGTATTTTTGGTGTGGTTTGGTGTGTGTATAT 4000 
15 . 2 -------------- ----------9---------- - 8------------------------------------------- 4000 
15 . 3 ------------------------9-----------8------------------------------------------- 4000 
HPV39 AATGGATATGATATAGTACTGTATATGTATGTGCATTGTGCATAACTACTGTACATAGCTTTTTATATTTTTTTTTGTTA 4240 
15.2 - - --------------- ------------------------------------------9-------------------- 4240 
15.3 -------------------------------------------------- ---------9-------------------- 4240 
Figu re 4.12: Alignment of HPV 39 (GenBank access ion num ber M62849) with the HPV 39 seq uences 
from clones, 15.2 and 15.3. Point mutations were detected throughout the genome. The mutations are 
highlighted in yellow. The asteriks (.) inbetween sequences indicate missing regions where no mutations 
were identified and therefore the sequence alignments for those regions are not shown. 
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4.3 Discussion 
The detection of HPV types in clinical samples is dependent on the methodology applied. 
The Roche Linear Array HPV genotyping test used in Chapter two detected 12 different 
HPV types in the specimen HH015 (Figure 4.5). The pyrosequencing method used in this 
chapter identified only seven HPV types from the same specimen, namely HPV 16, 30, 
39, 40, 56, 74 and 86. The differences in the HPV types identified by the two detection 
methods are highlighted in Table 4.2. Among the seven HPV types detected by 
pyrosequencing analysis, HPV 16, 39, 40 and 56, are included in the Linear Array 
detection test. However, HPV 56 was not detected by the Roche Linear Array HPV 
Genotyping test although it was part of the panel of HPV types that could be detected. It 
is possible that HPV 56 was not detected by the PCR-based Roche Linear Array HPV 
Genotyping test due to low levels. PCR-based methods may not be effective for HPV 
types with low DNA levels, especially in HH015 sample which had multiple HPV 
infections. Primer competition between different genotypes in PCR reactions could also 
explain the failure to detect HPV 56 by the Roche Linear Array HPV Genotyping test. 
This implies that PCR does not equally amplify the different HPV genotypes. According 
to the Roche Linear Array Genotyping test's manual, the test can detect HPV DNA at 
various concentrations but detection is also dependent on the HPV type. Therefore, 
assuming that HPV 56 had a low viral load, it was not amplified to detectable levels. On 
the contrary, pyrosequencing is more sensitive (Wicker et al., 2006, Gharizadeh et al., 
2005), therefore may be more reliable for samples negative with PCR methods. This is 
because in pyrosequencing, a single ssDNA fragment was clonally amplified to generate 
several copies of the same DNA molecule. This occurred for every fragment of DNA 
generated during the nebulisation process (Figure 4.2) thereby ensuring that each strand 
was sequenced. Unlike in PCR reactions where nucleotides may get depleted after a 
number of reactions, during pyrosequencing, the nucleotides are constantly being added 
at the start of each cycle. This ensures the continuity of sequencing process without the 
limitations of reagents. The RCA on DNA before pyrosequencing, which was not 
performed before PCR, improved the DNA concentration in sample hence this could 
have improved HPV 56 DNA level. This may have contributed to the detection of HPV 
56 by pyrosequencing and not by Roche Linear Array HPV Genotyping test. 
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In addition to HPV 56, three types (HPV 30, 74 and 86) not included in the Roche Linear 
Array HPV Genotyping test were detected. The viral load of these types was unknown 
but one can speculate their viral load may have been present at intermediate or high level 
for them to be identified. Although they were detected, the coverage of the sequences 
from these genomes was low compared to that of HPV 39 (Figure 4.7). This may imply 
that the DNA concentration for these three HPV types was lower than that of HPV 39. 
The question of sensitivity of pyrosequencing with regard to viral load could be solved by 
quantitating each HPV type DNA level and compare to the results obtained by 
pyrosequencing. However, this was not achieved due to time constraints. 
Pyrosequencing failed to detect nine types (HPV 45, 52, 53, 55, 59, 70, 71, 81 and 84) in 
Table 4.2 that were detected by the Roche Linear Array HPV Genotyping test. Although 
the pyrosequencing was able to detect multiple infections in the specimen, some of the 
high-risk HPV types known to be present were not detected. While it is possible that the 
viral load of each type may have influenced its successful identification, there is the 
possibility that pyrosequencing may not effectively identify all types in multiple 
infections. This may be due to differential viral loads of the different HPV genotypes. 
The detection of multiple genotypes in a single specimen may be a challenge for the 
pyrosequencing of whole genomes as opposed to peR amp Ii con sequencing. In previous 
studies on HPV genotyping by pyrosequencing, HPV peR products amplified by general 
primers GP5+/6+ and MY09/11 were used (Gharizadeh et ai., 2001). The peR products 
were primed with the GP5+ primer before pyrosequencing. This resulted in accurate 
genotyping of samples. peR products are easier to sequence because of small size. The 
use of HPV general primers improved sequencing by increasing the sensitivity for HPV 
DNA. However, in the presence of non-specific amplification in some of the samples or 
multiple types of HPV, pyrosequencing resulted in mixed signals (Gharizadeh et ai., 
2001). This was improved by using HPV-specific primers in pyrosequencing (Gharizadeh 
et ai., 2005). In comparison, the pyrosequencing in our study did not use HPV -specific 
primers and complete HPV genomes were sequenced after non-specific ReA of circular 
DNA from specimen. Therefore, this could have contributed to identification of only a 
few types (seven) compared to the 12 detected by the Roche Linear Array HPV 
Genotyping test. Samples with multiple infections may be particularly problematic due to 
the multiple sequence signals from all the genotypes in one specimen. This could have 
resulted in mixed sequence peaks which were difficult to analyse on the system 
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(Abmadian et al., 2006). Multiple signals could have been generated in the sequencing of 
the conserved regions like the E 1, E2 and L 1, where the simultaneous addition of 
identical nucleotides was possible. This could have made it difficult to determine the 
correct number of incorporated nucleotides (Ronaghi, 200 I). According to Gharizadeh 
and colleagues (2001), genotyping by pyrosequencing was found to be most effective in 
single HPV infections although typing was also possible when there were few dominant 
types and low background from other infecting HPV types (Gharizadeh et a/., 2001). This 
could explain why only a few HPV types were detected by pyrosequencing analysis, 
which seemed to reflect the HPV types that seemingly, had higher viral loads compared 
to the others. 
The HPV 39 band was the most intense of all the HPV types detected by the PeR-based 
Roche Linear Array HPV Genotyping test. The higher intensity of the HPV 39 band in 
the Roche Linear Array HPV Genotyping test (Figure 4.5) indicated a higher viral load in 
comparison to the other HPV types present in the specimen. Results from pyrosequencing 
showed a complete genome of HPV 39 (Figure 4.7d). The presence of HPV 39 in 
abundance could have contributed to its full length sequencing compared to the short 
sequences from other HPV types (Figure 4.7b, c, f and g). HPV 40 genome was almost 
fully sequenced as there were only a few (73) bases missing in the assembled sequence 
(Table 4.1 and Figure 4.7e). HPV 16 was completely sequenced but assembled into 
several overlapping fragments that constitute a complete genome (Figure 4.7a). The other 
HPV types (74, 86, 30, 56) were only partially sequenced (Figure 4.7b, c, f and g, 
respectively). 
Several of the sequences from pyrosequencing were identified as human DNA. This was 
expected since the origin of sample was human cells. As for supposed hits to other 
organisms, with the exception of bacteria and endogenous viruses, these represented 
similarities with human DNA rather than being present in specimen DNA. Bacteroides 
fragilis is a commensal organism within the human gut, which causes opportunistic 
infection in HIV immunosuppressed individuals (Wexler, 2007). Opportunistic infections 
by this organism can occur at any site, including the genital area (Wexler, 2007). 
Therefore the presence of bacteria could have been from the sampling. Prevotella 
intermedia is a gram negative anaerobe which can cause infections of the oral and genital 
tract (Finegold, 1995). The organism was therefore presumed to be present in the genital 
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tract of the individual. HERV-K is an endogenous virus that is commonly found in 
human DNA and does not cause infection (Boller et al., 1993). The other organisms 
which were identified (Figure 4.6) from other sequences indicated sequence similarities 
to DNA rather than their presence in human sample. The Pan troglodytes, for example, 
have a common ancestry with human hence the homology to some of the DNA 
sequences. 
The abundance of HPV 39 in the sample provided competitive advantage over other 
types digested with EcoRl when cloning was performed; therefore the RCA clones 
sampled had HPV 39 sequence. This was also reflected in the DNA bands shown in 
agarose gel after restriction enzyme digestion (Figure 4.8). The more abundant HPV 39 
'suppressed' the presence of other HPV types at low viral load. As a result, HPV 39 was 
the only type investigated for recombination within HPV genomes. There were no 
recombination events detected within HPV 39 sequences analysed. These observations 
were from only two clones and therefore may not reflect the correct impression. More 
cloned HPV genomes need to be analysed. Due to time constraints, analysis was 
performed on DNA cleaved by one restriction enzyme, EcoRI. 
Although no recombination was detected in HPV 39 sequences, several point mutations 
were identified within different genomic regions. The two sequences analysed revealed 
the occurrence of point mutations (Figure 4.12). This confirms other observations that 
sequence variations are common within HPV genomes. In a study of variation among 
HPV types by Stewart and colleagues (1996), HPV 39 sequences showed two nucleotide 
changes within the Ll ORF (Stewart et al., 1996). In our study, several point mutations 
were noted within various ORFs including El, E2IE4, E5, and L2. These sequence 
variations potentially signified variants of HPV 39, which increase genomic diversity of 
HPV. In the event of recombination, some regions which belong to other HPV sequences 
would have been identified within the HPV 39 genome. For example, a 20bp region from 
HPV 16 identified within HPV 39 genome sequence could have been an indication of 
recombination between HPV 16 and HPV 39. 
Most HPV infections appear to be clonal (Levi et al., 2002; Vinokurova et al., 2005), but 
co-infection with different HPV types is very common only in HIV infected individuals 
(Moodley et al., 2006). Therefore, there is a unique opportunity for new recombinant 
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HPV types to be generated within the host (Angulo and Carvajal-Rodriguez, 2007). 
When considering the high prevalence of HIV globally, HPV recombination might be 
favoured due to multiple persistent HPV infections in HIV positive women (Varsani et 
az', 2006). 
The discovery of the BPCVI was considered to be a result of possible recombination 
between PVs and PyVs (Woolford et al., 2007). The detection of possible recombination 
between these two subfamilies of Papovaviridae may signify that recombination is more 
likely to occur between HPV s, which are more closely related to each other than PV s are 
to the PyVs. 
Since the methodology for detecting recombination has been identified, it is promising 
that recombination can be detected among individuals with multiple HPV infections and 
HIV immunosuppression. 
The presence of additional HPV types as detected by pyrosequencing indicates the need 
to incorporate additional detection methods in HPV screening. It also suggests increased 
diversity of HPV types infecting women with HIV co-infection. The current methods of 
choice are HC2 assay and the Roche Linear Array HPV Genotyping test. Although these 
methods detect most clinically relevant HPV types, some types can easily be missed due 
to non-inclusion in the test method. The HPV types detected by the pyrosequencing 
method could be incorporated in the current Roche Linear Array HPV Genotyping test to 
increase the spectrum of HPVs detected in HIV infected individuals. Since HPV 30, 74 
and 86 were detected in one specimen, their prevalence in this HIV population required 
investigation by an appropriate method. This was followed on by the application of type-
specific PCR on all the specimens, refer to Chapter 5. 
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Chapter 5 
peR screening of clinical specimens for additional 
HPVtypes 
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5 Introduction 
The use of PeR-based methods in HPV detection has had huge successes in clinical 
assessment of HPV infection cases. The Roche Linear Array HPV Genotyping test is one 
of these methods; however, despite its successful application in HPV detection, it has its 
limitations in identifying all types in multiple infections. The inability of this method to 
distinguish HPV 52 from the other closely related HPV types, for example, also limits 
accuracy in reporting HPV 52 prevalence. 
The application of HPV type-specific peR in diagnostics has proved to be very useful in 
improving the accuracy of results obtained in epidemiological studies. This method is 
often used alongside other detection methods and is applied to confirm or refute certain 
results due to its increased sensitivity. There is no competition for primers as observed in 
most peR reactions using multiple primers and it is appropriate for amplification from 
samples with low HPV DNA viral load. However, one of the drawbacks for its 
application is that the primers for specific genotypes are 'in-house' developed. There are 
no commercially available type-specific primers for each genotype. Another disadvantage 
for using type-specific primers is the need for multiple parallel peR reactions for 
amplification of HPV types and post-amplification identification of types. This makes 
this process labour intensive. For these reasons, type-specific peR can not be applied to 
huge samples in epidemiology, diagnostic and clinical studies (van den Brule et at., 2002; 
Lin et at., 2008). 
In this chapter, a study of the prevalence of three additional HPV types (HPV 30, 74 and 
86) is reported. These types are not included in the cocktail of probes detected by the 
Roche Linear Array HPV Genotyping test, but were detected by pyrosequencing of DNA 
from one clinical specimen, HH015 (section 4.2.2). The prevalence of these types among 
all the women in the study was not known. Therefore, it was relevant to investigate 
prevalence of HPV 30, 74 and 86 by type-specific peR among all the women. 
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5.1 Materials and Methods 
5.1.1 Primer design 
Primers were designed to target only the HPV type under investigation. Therefore 
primers specific for HPV 30 (GenBank accession number X74474) were designed to 
target a short amplicon of 345bp within the E6 gene. Primers that amplified HPV 74 
subtype AElO (GenBank accession number AF436130) and HPV 74 (GenBank accession 
number U40822) were designed to amplify a 329bp (Table 5.1). HPV 86F and HPV 86R 
primers were designed from a 241 bases sequence obtained from pyrosequencing in the 
previous chapter. The primers amplified a 236bp fragment and the primer sequences 
corresponded to HPV 86 (GenBank accession number AF349909) at positions within the 
E6 gene. The primers are shown in Table 5.1. 
5.1.2 Type-specific peR amplification of HPV DNA 
The PCR mix for amplification of HPV 30 was set up as follows: IX GoTaq DNA 
polymerase buffer (Promega, Madison, USA), 1mM MgCb, 200~M dNTPs, 0.65U 
GoTaq DNA polymerase enzyme (Promega, Madison, USA), 2~1 of DNA template and 
400~M of each primer in a 25~1 reaction volume. DNA template used was extracted from 
each of the 109 cervical specimens. The dNTP solution contained nucleotides (dATP, 
dCTP, dGTP and dTTP) for incorporation during primer extension. The MgCb 
concentration was adjusted to 2mM for the amplification of HPV 74. The enzyme 
catalysed the addition of nucleotide bases at the 3' end of the DNA strand. PCR cycling 
conditions for amplification of HPV 30 and 74 were set as follows: 94°C for 10 minutes 
for denaturation of ds DNA, 35 cycles consisting of 94°C for 40 seconds, 55°C for 40 
seconds for primer binding to DNA template, 72°C for 40 seconds for extension of bound 
primer and a final hold at 72°C for 10 minutes for the fmal elongation of bound primer. 
PCR mix for amplification of HPV 86 was the same as for HPV 30 amplification, except 
for the difference in primers. The annealing temperature was adjusted to 5fc for the 
amplification of HPV 86 while the cycling conditions were kept the same as above. The 
amplified products were electrophoresed on a 2% agarose gel as outlined in Appendix 
Aiii. 
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Table 5.1: Type-specific primers for the amplification ofHPV 30,74 and 86 
Primer Sequence Position Amplicon size (bp) 
HPV30F 5'-TGAGGT ACAAGAAACATCGTTGC-3' (23) 158-180c 345 
HPV30R 5' -CGTACGTGATATTCTGTGAAACC-3' (23) 503-481c 
HPV74F 5'-TGCTGGACAACATGCATGGAAAA ATCCTAC-3' (31) 418-448a, 329 
3365-3395b 
HPV74R 5'- CCTCTGTACCTGTATTTTCCGCCATGT -3' (27) 745-719a, 
3696-3672b 
HPV86F 5'-GTTTGTAGGAGTGTGGCATCC-3' (21) 29-1Oc 236 
HPV86R 5'-TTGTACTGCCAAGTTTCTGTCC-3' (22) 7781-7802c 
a Position of primers in the HPV 74 A£10 subtype (AF436130) within the £61£7 genes. b Position of 
primers in the HPV 74 (U40822) within the L1 gene. c Primers located within the £6 gene. 
5.1.3 Cloning and sequencing 
The cloning and subsequent sequencing was performed to verify that the correct 
amplicon had been amplified by the respective primers. PCR amplicons from HPV 30, 74 
and 86 (amplified from specimen HH015) were excised from gel and purified according 
to protocol in Appendix Av. The purified amplicons were ligated into pGEM®-T Easy 
vector according to procedure in Appendix A vi using the pGE~ -T Easy cloning system 
(Promega, Madison, USA). The plasmid vector was transformed into E.coli (Appendix 
Avii) for replication and DNA was isolated from 5 ml bacterial culture (Appendix Aii). 
Purified DNA was sequenced using the M13 universal primers (Appendix Bii) to confirm 
that the correct HPV type had been amplified from specimen. Sequencing was performed 
at Macrogen, Korea, according to the chain termination method as described in Appendix 
Aviii. Analysis of sequences was done using Chromas version 2.01,2001 and DNAMAN 
program for windows version 5.2.9 (Lynnon Biosoft, © 1994-1999). 
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5.2 Results 
5.2.1 Type-specific peR amplification 
PCR screening of all the specimens was performed using type-specific primers in order to 
determine the prevalence of each of HPV 30, 74 and 86 among 109 HIV positive women. 
Primers specific to each of the HPV types 30, 74 and 86 were used to amplify short 
fragments from clinical specimens from 109 HIV positive women. Amplicons from 
specimen HH015 which were cloned and sequenced showed that correct HPV types were 
amplified (Table 5.2). For each sequence searched by BLASTN 
(www.ncbi.nlm.nih.govlhlast), other related HPV types were also identified, although 
with less homology (Table 5.2). A phylogenetic analysis of these HPV types showed that 
they belong to the same species as shown in Figure 5.4. 
Type-specific primers used in the amplification of HPV 30, 74 and 86 successfully 
amplified the expected PCR products from other specimens positive for each respective 
HPV type. Figures 5.1-5.3 illustrate the results of the amplification. 
Table 5.2: Blast results of clones of peR amplicons from different HPV types. 
Amplicon from length of 0/0 Identity to any other 
sequence (bp) identity HPVtype 
HPV30 400 98 88%-HPV53 
HPV74 369 96 90%-HPV 74cds 
HPV86 238 96 79%-HPV 84 
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300bp 
-
- - -
-
--- - -34 5bp 
Figure 5. 1: Representa tive aga rose gel analysis after pe R amplification of H-PV 30 from clinica l 
specimens. A negative control with water and a positive control us ing DNA from HHOl5 were included in 
each amplification. The specimens HH06 I, HH063 and HH067 were positive fo r HPV 30. 
300bp 
Figure 5.2: Rep resenta tive agarose gel of th e a mplifica tion of HPV 74 from 109 clinical specimens. 
The three specimens in this ampli fi cation that were positive for ~I PV 74 were HH048, HH054 and HH055. 
-
"""., 
.... , 
_ f- """" 
-
Figure 5.3: Representative aga rose gel after the a mplification of HPV 86 from clinica l specimens. 
Spec imen HH062 was positive for HPV86 in this figure. 
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5.2.2 Prevalence of a dditio na l types (H PV 30, 74 and 86) 
Each of the 109 specimens was screened for the presence of each of the three HPV types. 
The specimens positive for each of the three HPV types are shown in Table 5.2. HPV 30 
had the highesl prevalence (15%, 161109), HPV 74 prevalence was 13% (141109) and 5% 
(51109) of the women were infecled wilh HPV 86 (Table 5.3). 
Table 5.3: The dist r ibu tion of HPV 30, 74 and 86 among 109 HI V positive women 
Inlicriplion .'. 'irnls 
IU'V n~.livr 
IIPV 30 hhOIS, hh022, hh031. hh034.hh040.hh04 I, hhOSI, hh054. hhOSS, hh06 I, hh06J, hh061, hh016.hh082.hh095, hhI02 
UPV 74 hh015. hh020. hh022. hhOl4. hh048, hhOS4, hhOSS,~, hh074, hhQ8) , hh081. hh097, hh1 07, hhlll 
IIPY 86 hhOll , hhOIS, hhOJ4, hh062,hh099 
a.O!; 
L.......J 
100 HPVH "ElO AF340130 
HPV7<l U40822: 
lOC HPV55 
II HPV13 
- Low ... .".. 
lOOr HPV~ 
HNo. 
ICC 
'''' HPVIl 
= l< HI?V66 
HFV56 iii"""'"", 
-
H)( Hf>VJO 
'''' 
HPVS] 
HEVal = ., 
HPV61 
10< HP'Vi2 
, 
HPV83 
HPV84 r- ""'" ... .".. 
1 HPVc-andes 
I HPVc.and61 
-
Figure 5.4: Phylogenetic tree of dirrerent I-lPV Iypes. The full length genome sequences obtained from 
GenBank (NCB I) were aligned using the Jukes and Cantor joining and a bootstrapping of 100. HPV 30 is 
closely related to the high-risk HPV types 53, 56 and 66, a high-risk clade. HPV 74 is related to the low-
risk types 55 and 13, whi le HPV 86 shows close relationship to HPVs 87 and 84. Both HPV 74 and HPV 
86 are phylogenetically classified as low-risk HPV types. 
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5.3 Discussion 
In Chapter 4, three HPV types (30, 74 and 86) were detected in one specimen using 
pyrosequencing technique. These were not detected by the Roche Linear Array HPV 
genotyping test. Therefore it was relevant to investigate the prevalence of these HPV 
types in all the other women. To achieve this, type-specific PCR was used to amplify 
each of the three HPV types. 
HPV 30 had the highest prevalence (15%, 16/109) among the three HPV types (Table 
5.3). This is significant, as its prevalence was higher than the prevalence of HPV 16 
(14%, 15/109) in this population study. This may indicate that HPV 30 could be a 
commonly occurring type among HIV positive women. It was first isolated from 
laryngeal carcinomas and also detected in a few genital lesions (Kahn et ai., 1986; IARC, 
2007). This type has not been reported in many epidemiological studies due to its 
exclusion in the commercial kits for HPV detection. HPV 30 is not included in these kits 
because its risk for cervical cancer has not been proven since it has been found mostly in 
benign lesions. Two studies have reported on the prevalence of HPV 30 and only one of 
them was on HIV positive women (Banura et aI., 2008; Singh et ai., 2009). Among the 
HIV positive women, overall HPV 30 prevalence was 6% (40/647) and in women with 
HSIL, it was 9% (6/69) (Singh et ai., 2009). The prevalence in the general population 
was reported as 9% (9/95) (Banura et ai., 2008). 
HPV 30 is classified in the genus alpha-papillomavirus, species six, together with HPV 
53,56 and 66. Among the species six group, HPV 56 is the only type categorised among 
the high-risk while 53 and 66 are probable high-risk types (Schiffman et ai., 2009) 
(Chapter 1, section 1.5.1). A phylogenetic analysis of HPV 30 indicated that it is closely 
related to HPV53 (Figure 5.4) and therefore should probably be considered as a high-risk 
type. Results from Singh and colleagues' (2009) study indicated that infection with HPV 
30 among HIV positive women led to HSIL (Singh et ai., 2009). For this reason, its 
prevalence in the population should be monitored. This can be achieved when HPV 30 
has been included in the commercially available HPV detection kits that may be used in 
cervical screening (HC2 and Roche Linear Array HPV Genotyping test). 
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HPV 74 was slightly less common than HPV 30, with a prevalence of 13% (14/109). It is 
a mucosal HPV related to the low-risk types in species ten of the genus alpha-
papillomavirus; HPV 6, 11, 13, 44 and 55 (IARC, 2007; Longuet et ai., 1996). A 
phylogenetic tree of these types indicated that HPV 74 is more closely related to HPV 44 
and 55 (Figure 5.4). This HPV type is a non-oncogenic mucosal type associated with 
LSIL and has been reported in vaginal intraepithelial neoplasia (VaIN) (Wheeler, 2002; 
Safaeian et ai., 2007). HPV 74 was initially isolated from immunosuppressed women 
who had renal transplants and had LSIL of the vagina. It was not isolated from any 
immunocompetent patients (Longuet et ai., 1996). Recently, however, HPV 74 has been 
reported in 2/82 (2%) of HIV positive women and a lower prevalence (1 %, 8/868) in HIV 
negative women (Banura et ai., 2008). This may reflect that HPV 74 occurs infrequently 
and can effectively be cleared by the host immune system of immunocompetent 
individuals (Longuet et ai., 1996). The presence of HPV 74 in renal transplant patients 
and HIV positive women indicate the susceptibility of immunocompromised women to 
HPV 74. Therefore, HPV detection methods may need to include HPV 74 especially 
when monitoring HPV infection in HIV positive populations. 
HPV 86 was the least common of the three types, with a recorded prevalence rate of 5% 
(5/109) among the HIV infected women. It is a mucosal low-risk HPV type responsible 
for genital warts as well as CIN (Wheeler, 2002). HPV 86 is classified into the genus 
alpha-papillomavirus, species three, and is phylogenetically related to the HPV 84, 87, 
61, 72,81 and 83 (IARC, 2007). Figure 5.4 shows the relationship between HPV types in 
species three of the alpha-papillomavirus genus. In a recent study among HIV positive 
women, the overall HPV 86 prevalence was 35/647 (5%) and in women with cervical 
lesions, was 14/212 (7%). Of the 69 women with HSIL, six of them (9%) were positive 
for HPV 86, thus linking HPV 86 to HSIL in HIV positive women (Singh et ai., 2009). 
The low prevalence ofHPV 86 in Singh and co-workers' (2009) study and our study may 
suggest that it is a rare type in HIV positive women and probably more rare in the HIV 
negative population. 
The identification of these mucosal HPV types in HIV positive women may suggest that 
HPV diversity among these women is greater than anticipated. There could be more HPV 
types that are not necessarily associated with risk of cervical disease/cancer in 
immunocompetent women, but are relevant to immunosuppresed patients, that remain 
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undetected. Since type-specific peR may not be practical to use in large epidemiological 
studies, current detection methods need to cover a wider spectrum of HPV types. Most 
detection methods include the high- and probable high-risk types but few of the low-risk 
types. More coverage of the low-risk HPV types and some types considered to be of 
undetermined risk (Table 1.3) in the detection methods would benefit screening for 
cervical disease among the HIV positive women. 
98 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 6 
6 Conclusion 
HIV positive women are infected with more HPV types than their HIV negative 
counterparts. The wider HPV range in these women demonstrates the need to continue 
the development of polyvalent vaccines for the prevention and treatment of cervical 
disease in women. Vaccination before sexual debut has been instrumental in the 
prevention of infection with HPV 6, 11, 16 and 18. However, the vaccines may not be 
effective against infection with other HPV types in HIV positive women who are at 
higher risk of infection than HIV negative women. Development of polyvalent 
prophylactic vaccines incorporating the most prevalent HPV types among HIV positive 
women would reduce the burden of cervical disease in South Africa. Ultimately, this 
would also decrease mortality from cervical cancer in the general population. The most 
frequently occurring HPV types, in this study in HIV positive women were HPV 61, 66, 
53 and 58, which could be added to the HPV types targeted for vaccine development, 
especially for high HIV prevalence areas. The high prevalence of HPV types that are not 
included in the current vaccines emphasises the need to develop vaccines that protect 
against a wider range of HPV types. From this study, low-risk HPV 61 had the highest 
prevalence (24%, 26/109), indicating that it is a potential threat to the immunosuppressed 
women. The prevalence of the high-risk HPV 58 (17%, 19/109) and probable high-risk 
types 53 (17%, 18/109) and 66 (18%, 20/109) also potentially increases the vulnerability 
of these women to cervical disease/cancer. In addition to these, HPV 45, which was also 
found to be common among HIV positive women in a different study in Cape Town 
(Marais et ai., 2008), can be considered as a vaccine candidate in order to reduce HPV 
infection among HIV women. 
The Roche Linear Array HPV Genotyping test is currently not equipped to identify all the 
HPV types in the HIV positive immunocompromised population. This was highlighted by 
the identification of HPV types not included in the Roche Linear Array HPV Genotyping 
test by using type-specific PCR (Table 4.2). As observed in this study, there were low-
risk HPV types detected frequently among these women, therefore it would be beneficial 
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to include more HPV types in detection kits than are currently incorporated. The 
application of other detection methods in addition to the PCR-based method identified 
more HPV types, thus re-affirming the need for more HPV types to be included in 
diagnostic detection kits. The identification of HPV 30, a type closely related to the high-
risk HPV 56, indicated the possibility that HIV infected women may have more 
'unclassified' HPVs which can cause HSIL than those currently classified as high-risk 
types. Although HPV 30 is not among the high-risk HPV types, it can lead to HSIL in 
HIV positive individuals as was observed by Singh and co-workers (Singh et ai., 2009). 
The number of studies on HPV 30 and HSIL cases are however limited, therefore more 
studies on this type are required to determine its risk in cervical disease or cancer. 
While PCR-based methods are considered sensitive, it is worth noting that different PCR 
methods can detect certain HPV types better than others, especially in multiple infections. 
For example, the Roche Linear Array HPV Genotyping test for detection ofHPV 52 and 
31 was found to be poor compared to the detection of these types using the LiP A 
detection method (Castle et ai., 2008). As a result, some HPV types may be 
underestimated and this certainly impacts on the prevalence of HPV types reported in 
epidemiological studies. The use of at least two HPV detection methods would be ideal to 
accurately report on HPV prevalence. 
The use of the Roche Linear Array HPV Genotyping test alone may not be reliable for 
the estimation of HPV 52 prevalence. In research work, it would be beneficial to use 
another method for the detection of HPV 52 in samples positive for the mixed group, for 
example type-specific PCR. This method is very useful in confirming disputed results or 
can be used as a third method where two other methods are discordant. For the purpose of 
clinical management of women, it would be safer to assume presence of HPV 52 
whenever a sample is positive for the mixed group (Castle et ai., 2008). The use of the 
recently developed BSGP5+/6+ primers can also improve the identification of HPV 52. 
In addition, these primers can detect HPV 30, 74 and 86 (Schmitt et ai., 2008). The 
coupling of the Roche Linear Array HPV Genotyping test genotyping with the 
BSGP5+/6+ primers could significantly increase the spectrum of HPV types detected. 
Therefore, this would significantly improve HPV monitoring among HIV positive 
women. 
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Pyrosequencing of DNA from HPV and HIV infected individual indicated the presence 
of more HPV types in addition to those detected by Roche Linear Array HPV Genotyping 
test. Despite its inability to detect all the types that were genotyped by the Roche Linear 
Array HPV Genotyping test, pyrosequencing can effectively be used in identification of 
novel HPV types as well as those currently not included in PCR-based methods. It can 
also give an idea of differential viral loads. The efficacy of this method for detecting 
multiple HPV infections may be improved by the use of multiple HPV -specific primers 
during sequencing (Ahmadian et at., 2006). Pyrosequencing can also be applied to the 
identification of HPV 16 variants. This would benefit infected women since presence of 
HPV 16 variants can be used as a marker for cervical disease among HIV positive 
women. Successful identification of women at risk would therefore allow necessary 
intervention to prevent cervical cancer. 
Although we did not detect recombination in the analysed HPV genome, there is a 
possibility of recombination occurring in HIV positive women with multiple HPV 
infections. Through the application of RCA and metagenomic analysis, which includes 
pyrosequencing, it is possible to analyse several HPV genomes for recombination. The 
analysis of more HPV genomes can increase the possibility of detecting recombination. 
In our study, however, we were able to analyse only one HPV genome. 
The genomic diversity of HPV can be fully understood only when efficient diagnostic 
tools are available. Identification of HPV 16 variants by sequencing the LCR indicated 
the high level of sequence variation, which could give rise to even more diverse HPV 
genomes. This high level of sequence variation within the LCR was expected since the 
LCR is under less mutation restriction when compared to the coding regions. The 
observation of new mutations in this region suggests that frequent point mutations occur 
within the LCR. The mutations observed in HPV 16 may also suggest that a similar 
pattern of variation may occur in other HPV types. An investigation into the diversity of 
other HPV types that are phylogenenetically unrelated to HPV 16 showed presence of 
limited genomic diversity. This was observed in variants of HPV 53, 56 and 66, which 
have also been identified among South African women (Prado et ai., 2005). The presence 
of point mutations within HPV 39 genome indicated sequence variations that can increase 
genomic diversity among HPV types. 
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In conclusion, HIV positive women have increased diversity of HPV infection from both 
low- and high-risk HPV types. This necessitates constant monitoring of these women to 
prevent progression to cervical cancer. All the known variants ofHPV 16 (E, A, AA, and 
At) were identified among this group of women. There were no recombination events 
observed in the analysed HPV 39 genome. There is need for analysis of more HPV 
genomes and different HPV types for identification of recombination in HPV s. 
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Appendix A 
Standard Methods 
i. Bacterial growth media and growth conditions 
Bacterial cultures were grown in Luria-Bertani (LB) broth containing 100~g/ml of the 
antibiotic ampicillin. The ampicillin was added for selective growth of transformed cells. 
The LB consisted of the following: 5g bacto-typtone, 5g yeast extract, 109 NaCI and 
made up to lL with distilled water and autoclaved. Luria-Bertani agar (LA) was also 
made up with the same components, and in addition contained 15g/L of agar. All growth 
was incubated at 3 t C for 18 hours, with liquid cultures incubated on a shaker. The 
bacterial strains used for transformation were DH5a strain of E.coli (Invitrogen, USA). 
ii. Small scale DNA extraction 
DNA was isolated from 5ml overnight (18 hours) bacterial cultures according to QIAprep 
Spin miniprep Kit protocol (Qiagen, Gaithersburg, USA). This extraction method is 
based on the alkaline hydrolysis of cells in Sambrook et al., 1989. After centrifugation, 
the pelleted cells were resuspended in buffer containing Tris-CI, EDT A RNase A. The 
cells were lysed by incubation in alkaline lysis buffer with 200mM NaOH and 1% SDS 
to release proteins and nucleic acids. The solution was neutralised with potassium acetate 
before centrifuging. The RNase removed any contaminating RNA and SDS denatured 
proteins, which were removed in a pellet by centrifuging. In the presence of sodium salts, 
the DNA in solution was bound to a column of silica membrane and precipitated with 
isopropanol. Any contaminants were washes through the membrane. Precipitated DNA 
was washed with buffer containing ethanol and eluted with Tris-CI-EDTA (TE) buffer by 
releasing bound DNA into solution. 
iii. Agarose gel electrophoresis of DNA 
Gel electrophoresis of DNA was performed on 0.8% agarose gels at 100 volts for 
genomic DNA and fragments larger than one kilobase (kb). DNA separates on agarose 
gel according to size of fragment. Electrophoresis of PCR amplicons of 500bp or less was 
carried out on 2% agarose gels at 120 volts. The separation of larger fragments (lkb or 
larger) was performed using 0.8% agarose gel. All agarose gel contained ethidium 
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bromide at a concentration of 0.5 Jlg/ml for DNA visualization on a UV transilluminator 
at 260nm (Sygene). IX Tris-Borate EDTA (TBE) was the buffer medium of 
electrophoresis. DNA fragment size was estimated by using the one kb O'Gene Ruler 
(range 10000bp-250bp) and 100bp O'Gene Ruler (range 1000bp-100bp) (Fermentas, 
USA) for large and small DNA fragments, respectively. 
iv. Restriction Enzyme Analysis 
Genomic and plasmid DNA was digested with EcoRI restriction enzyme (Fermentas, 
USA) in a 20JlI reaction mix consisting of 2JlI (IX) EcoRI buffer (Fermentas, USA), 
0.5JlI EcoRI enzyme, approximately 300ng DNA and made up to 20JlI with sterile 
distilled water. The mixture was incubated in 3 i C water bath for four hours. The enzyme 
was heat inactivated at 72°C for 5 minutes after the reaction. Digested DNA was 
electrophoresed on the appropriate percentage gel agarose (see iii). Other enzymes used 
for digestion of genomic DNA were BamHI and BglI. 
v. Gel purification of DNA 
DNA was purified from agarose gel slices according to the protocol of the Gel 
Purification Kit (Qiagen, Gaithersburg, USA). After restriction enzyme digestion or PCR, 
DNA was loaded onto the relevant agarose gel and electrophoresed, visualized on the 
long wavelength (345nm) and excised using a sterile blade. The excised gel slice was put 
into a 2.0ml eppendorf tube and purification was performed as outlined in above named 
kit. The gel slice was dissolved at 50°C in buffer at pH 7.5. The DNA was bound to a 
column of silica membrane and washed with ethanol for precipitation and eluted in TE 
buffer. DNA was either sequenced or used in subsequent reactions. 
vi. Ligation reactions 
Gel purified DNA was used in all ligation reactions in a 10 JlI reaction volume consisting 
of vector to insert ration of 1:3 for small DNA fragments and 1:20 for large (>3kb) DNA 
fragments. The vector used for cloning PCR products was pGEM®-T Easy (Promega, 
Madison, USA), and for cloning of whole genome of HPV, pUC19 (Amersham 
Biosciences) was used. pUC19 was linearised with EcoRI (see iv) and dephosphorylated 
at ends to prevent self-ligation. DNA was ligated using 1 U DNA Ligase enzyme 
(Promega, Madison, USA) in the presence of IX Ligase buffer (Promega, Madison, 
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USA). The ligation reaction was carried out at 4°C for 18 hours. DNA ligase enzyme 
catalysed the formation of phosphodiester bonds between two DNA strands. 
vii. Transformation 
Competent E.coli DH5a cells (Invitrogen, USA) were used for all transformation 
experiments. Transformation was carried out by using 20111 of competent bacterial cells 
with 5111 of ligation mix in a 1.5ml eppendorf tube. The tube was chilled on ice for 15 
minutes before heat-shocking at 3ic in a water bath for 1min and chilled on ice again 
for two minutes. 500111 of LB were then added to the transformation mix and incubated 
for a further 1 hour at 3ic, after which 100111 of the mix were plated out onto a LA plate 
with Ampicillin as a selective marker, 50 III of O.lM IPTG and 10 III of 2% X-gal. 
Incubation of LA plates was as mentioned in (i) above. 
viii. Sequencing of clones and sequence analysis 
Purified miniprep DNA was used for sequencing using the Sanger chain termination 
method, at Macrogen, Korea. The sequencing technique is based on the dideoxy chain 
termination method. The sequencing method required a template DNA to be sequenced, 
primers to initiate sequencing, DNA polymerase, fluorescently labelled nucleotides 
(dNTPs) and modified nucleotides (ddNTPs-ddATP, ddCTP, ddGTP and ddTTP) for 
termination of DNA strand elongation. Different reactions with DNA template were 
prepared with all of the requirements except the modified nucleotides. Only one of the 
ddNTPs was added to each reaction, where its incooperation into the DNA strand 
inhibited addition of further nucleotides. The ddNTPs do not have a 3' -OH, therefore no 
further phosphodiester bonds are possible after addition of a ddNTP. Synthesised 
fragments were denatured and resolved to one base size by gel electrophoresis. The DNA 
was visualised by UV light and the sequence was read off the gel image (Sanger et ai., 
1977). Sequence results were analysed using Chromas version 2.01,2001 and DNAMAN 
program for Windows, version 5.2.9 (Lynnon BioSoft, © 1994-1999). 
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Appendix B 
Vectors used 
i. pUC19 vector 
pUC19 
2.686 kb 
Ssp! 
HindIII 
Sphl 
Ps1i 
Sal 
XbaI 
hmHI 
5mu 
KpnI 
Sacl 
EcoR! 
Figure 1: pUC19 cloning vector (www.bioron.netlpUC19-dna.html) 
ii. M13 primers used for sequencing 
M13 Forward primer 5'-GTTGTAAAACGACGGCT-3' 
M13 reverse primer 5'-CAGAAgACAGCTATGAC-3' 
106 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
iii. pG EM-T Easy vector 
•...... 
""--:z::~::1 .. / ..... 
to<:_ .. :J.lS.~ .,' 
).1!1-' __ .!...'()..,:po1(~'··::!991 •••• 
pGE-\1-T Easy Veeto<' 
1.Okb 
~ 
• 
-
,. 
'. 
o 
.. ,. 
Figure 3: pGEM-T Easy cloning vector (www.biovisual.coml ... pGEM. 
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AppendixC 
i. Table 1. Primer sequences for primer-walking of HPV 39 genome 
Clone Primer Primer sequence (5' -3' ) Bases (bp) Position 
15.2 15.2F TCATCCTGTCCAGGTGCACTGC 24 7593-7614 
15.2.1F CGGTTGACCTTGTATGTCACGAGC 24 659-682 
15.2.2F CACAATTTAAAGAAACATATGG 22 1544-1565 
15.2.3F ACCACTTGCAGATGCAAAACTAGC 24 2451-2474 
15.2.4F TCGACAGTGTGCAGTCACAGAGC 23 3544-3566 
39R GGTTGGGCATACATACCTAT 20 7807-7826 
15.2.5F TGTTGTAGATGTGTCTCC 18 4489-4506 
15.2.6F TTCTTCAGCATCTACTAAATATGC 24 5404-5427 
15.2.7F TGCCTTTAGATATTTGTCAATCC 23 6298-6320 
15.3 15.3F CATGTCTTTACCTTAGGTTCAC 22 7521-7547 
15.3.1F TACAATGAAATACAGCCGGTTGAC 24 643-666 
15.2.2F CACAATTTAAAGAAACATATGG 22 1544-1565 
15.2.3F ACCACTTGCAGATGCAAAACTAGC 24 2451-2474 
15.3.4F TCGACAGTGTGCAGTCACAGAGC 23 3544-3566 
39R GGTTGGGCATACATACCTAT 20 7807-7826 
15.3.5F ATGTGTCTCCTGCACGTCCACC 22 4497-4518 
15.3.6F TTCTTCAGCATCTACTAAATATGC 24 5404-5427 
15.3.7F GATGTGTATGGGGACAGTATGTTC 24 6357-6380 
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